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KDM6B (JMJD3) is one of two known epigenetic modifiers responsible for the 
removal of the repressive histone mark, histone-3 lysine-27 trimethylation (H3K27me3), 
and has been shown to play a role in development, differentiation, and inflammatory 
stress response.  Unlike the other H3K27me3 demethylase, UTX (KDM6A), which is 
frequently mutated in hematopoietic malignancies, KDM6B is upregulated in a myriad of 
blood disorders.  This suggests that it may have important functions in the pathogenesis 
of hematopoietic cancers.  Here, we examined the role of Kdm6b in hematopoietic stem 
cell (HSC) fate decisions under normal and malignant conditions to evaluate its potential 
as a therapeutic target.  Loss of Kdm6b leads to a significant reduction in phenotypic and 
functional HSCs in adult mice, which increases with increased age.  Loss of Kdm6b 
results in the inability to maintain the HSC population post-transplantation in a dose-
dependent manner.  In addition, Kdm6b is necessary for HSC self-renewal in response 
to inflammatory, genotoxic and oncogenic stress. Kdm6b HSCs have a stress response 
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gene expression signature which overlaps significantly with immediate early response 
genes, genes associated with aged HSCs and genes involved in quiescence of HSCs. 
When stimulated with an inflammatory or proliferative agent, Kdm6b–deficient HSCs are 
not able to efficiently resolve gene expression programs, leading to delayed cell cycle 
entry and a self-renewal block, forcing them to differentiate once they commit to divide. 
Thus, Kdm6b is necessary for self-renewal of normal and leukemic stem cells, and 
KDM6B inhibition combined with proliferative agents may force differentiation and 





Chapter 1: Introduction 
1.1 Epigenetic Modifications are Dynamic and 
Reversible 
Within the nucleus, DNA is highly organized into chromatin consisting of nucleosome 
complexes comprised of histone proteins that can be modified at their N-terminal tails.  
These covalent post-translational modifications, termed epigenetic, including methylation 
and acetylation of the lysine (K) and arginine (R) residues, play a vital role in 
transcriptional regulation and chromatin architecture.  The epigenetic landscape also 
serves a role in cell type identity with modifications being inherited by daughter cells and 
serving as memory for those cells1–4.  There have been many enzymes that have been 
identified that are responsible for the placement of post-translational modifications of the 
histone tails.  These epigenetic ‘writers’ include histone acetyltransferases and histone 
methyltransferases.  EZH2, a histone 3 lysine 27 (H3K27) methyltransferase, is the well-
characterized writer component of the polycomb repressive complex 2 (PRC2) which also 
includes the subunits SUZ12, EED, and RbAp485.  PRC2 is responsible for the 
trimethylation of H3K27, which is associated with transcriptional repression6, and paused 
RNA polymerase II (RNA Pol II) at the promoters of PRC2 targeted genes7.  The 
placement of H3K27me3 by PRC2 has been shown to play an important role in X-linked 
inactivation8,9, as well as embryonic stem cell pluripotency (ESC) and development10–14.  
Because H3K27me3 repression plays a vital role in maintaining pluripotency of 
ESCs14, it stood to reason there must be a way to resolve expression of the genes 
necessary for differentiation.  Evidence of histone demethylases, so called ‘erasers’, 
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came when LSD1 (KDM1A), was discovered to act as a transcriptional repressor by 
removing the activating H3K4me2/1 chromatin modification by oxidative demethylation 
requiring the cofactor flavin15.  Since then an even larger family of proteins, the Jumonji 
C (JmjC) domain containing proteins have been discovered.  These enzymes also act as  
oxidative demethylases, but require iron Fe(II) and α-ketoglutarate as cofactors16,17. 
Bioinformatic analyses to identify JmjC domain proteins indicate that in humans this class 
of proteins contains 30 different genes that cluster into seven groups16–20.  Since the 
discovery of the enzymatic activity of JmjC proteins, many studies have uncovered their 
substrate specificities, including those responsible for the removal of the H3K27me3 
repressive mark: KDM6B and UTX. 
1.2 KDM6B as a Demethylase  
One of the seven phylogenetic branches of the JmjC protein groups is the 
UTX/UTY/KDM6B group of proteins.  UTX (also called KDM6A) protein is X-linked and 
escapes inactivation21 whereas the UTY protein in Y-linked.  These two proteins contain 
six tetratricopeptide repeats (TPR) domains along with a JmjC domain and are 88% 
homologous, with 82% homology within their JmjC domains22.  KDM6B, located on 
chromosome 17p13.1 in humans, is another member of this family.  While KDM6B still 
retains high sequence homology to UTX within its JmjC domain at 84%, it lacks TPR 
domains and the full length proteins are only 70% homologous22.  Computational 
modeling of the KDM6B:H3 complex shows three conserved domains: the JmjC domain, 
the linker domain, and the zinc binding domain, similar to that of UTX; however, within 
the zinc binding domain, there is a different angle of an α-helix which shifts the zinc atom 
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as well as the bound H3 peptide giving a slight difference in conformation between the 
two proteins23.  Additionally, while it has been shown that UTX undergoes a 
conformational change upon binding to H3 peptide24, KDM6B does not23.   
In 2007, six independent groups identified UTX and/or KDM6B as H3K27me2/3 
demethylases, but interestingly, despite the highly conserved sequence, UTY lacks 
demethylase activity18,19,22,25–27.  Agger et al showed that ectopic expression of UTX and 
KDM6B, led to a reduction of H3K27me2/3 levels in HeLa cells in a dose-dependent 
manner and indicated a higher specificity to trimethylation19.  The experimental approach 
by Hong et al in HEK293T cells indicated that as well as having H3K27me2/3 specificity, 
UTX can also demethylase H3K27me1, and the TPR domains may be necessary for this 
specific interaction22.  Conversely, while overexpression of KDM6B showed a global 
reduction in H3K27me3 and H3K27me2 in HEK293T cells, it also led to an increase in 
H3K27me1 levels due to the conversion of H3K27me3 and H3K27me2 indicating that 
while UTX can demethylase H3K27me1, KDM6B can not26.  While overexpression of both 
proteins led to a global reduction in H3K27me2/3 levels, knockdown of either protein led 
to varying results depending on the cell type.  
Enzymatic kinetics utilizing MALDI-TOF mass spectrometry indicate that KDM6B has 
a higher affinity for its substrates over UTX28,29, however, demethylation still required a 
high enzyme-to-substrate ratio19,25–27.  Jones et al. found that despite the slight 
conformational changes discussed previously, the same residues of the histone peptides 
needed for substrate recognition were identical between the KDM6B and UTX and they 
hypothesize that these shifts in conformation may explain higher KDM6B affinity23,28.  
Within the JmjC domain of KDM6B, there are three amino acids residues necessary for 
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chelating iron: His1390, Glu1392 and His147018.  Any one mutation, or combination of 
mutations, renders KDM6B catalytically dead, leaving it unable to demethylate 
H3K27me2/3 showing its dependency on iron18,19,27,28.  Additionally, KDM6B and UTX 
were both shown to have diminished enzymatic activity on synthetic  peptides, with UTX 
unable to recognize or demethylate H3K27me1 without the presence of intact H3 histone, 
indicating the necessity of the core histones and the possibility of other cofactors of 
KDM6B and UTX to exist22,26. 
In addition to being methylated at H3K27 the histone tail has also been shown to be 
phosphorylated by mitogen- and stress-activated kinases (MSK) at S28 creating a double 
H3K27me3S28p post-translational modification.  This modification leads to a 
disassociation of the PRC2 complex and an increase in gene expression30.  The presence 
of phosphorylation at S28 was also shown to result in the inability of KDM6B to 
demethylate H3K27me328.   
While the majority of the experimental evidence suggests that KDM6B is specific to 
H3K27me2/3, a more recent group studied its role as a methylarginine demethylase 
(RDM).  Using truncated recombinant proteins containing the catalytic domain of several 
JmjC proteins, they found that KDM6B was capable of demethylating synthetic 
H3K27Rme2a, and the method of methyl group oxidation to release formaldehyde is 
conserved between lysine and arginine demethylation.  Interestingly, formaldehyde 
dehydrogenase-coupled demethylation assays indicated that KDM6B demethylation of 
arginine is more efficient than lysine.  Given all this, however, KDM6B failed to show 
enzymatic demethylase activity on natural histone peptides31.  Despite its inability to act 
on natural occurring peptides in the context of the experimental design of Walport et al, it 
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is the first time that it has been shown that JmjC proteins, and KDM6B specifically, may 
play a dual role in demethylation. 
In addition to having possible histone demethylase role outside of H3K27me2/3, 
KDM6B has also been shown to regulate p53 post-translational modifications which 
influence its regulatory roles, protein interactions, and subcellular localizations32–37.  
Overexpression of KD6MB in neuronal stem cells (NSC) was shown to increase p53 
independent of transcription indicating that it helps stabilize p53 during NSC 
differentiation38.  In addition to stabilizing p53 the two proteins were shown to interact in 
NSCs, and wild-type KDM6B but not catalytically inactive KDM6B led to a reduction in 
p53 demethylation.  This demethylation correlated to an increase of p53 in the nucleus, 
whereas the mutant KDM6B led to an accumulation of p53 in the cytoplasm indicating 
that during neuronal differentiation KDM6B plays a very important role in regulating p53 
subcellular location in a demethylase-dependent manner38. 
1.3 KDM6B Plays an Important Role in Development 
 Given the role that H3K27me3 was seen to play in maintaining the pluripotency of 
ESCs, it stood to reason that one of the major roles H3K27me3 demethylases play an 
important role in the regulation of development.  Indeed, the pattern of KDM6B expression 
in embryonic stem cells has been shown to increase throughout differentiation12.  It has 
been shown that KDM6B begins regulating development at the first step of mammalian 
cell lineage commitment, prior to embryo implantation.  In order for implantation to occur 
the eight-cell blastomeres must first differentiate the outside cells into the trophectoderm 
(TE) and inside cells into the inner cell mass (ICM).  The TE is essential for implantation 
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as it interacts with the maternal uterus and forms placental tissue39.  KDM6B has been 
shown to play an important role in this lineage commitment by balancing PRC2 and 
controlling TE gene expression.  In mouse trophoblastic stem cells, PRC2 was found to 
be localized to the ICM, but KDM6B was expressed in both lineages.  Interestingly, this 
expression was found to be higher in the cytoplasm than the nucleus. Within the TE, 
KDM6B was found to bind to and decrease H3K27me3 at the promoters of Cdx2 and 
Gata3 leading to an increase in expression40.  These genes are previously defined 
master-transcription factors necessary for TE development41–43, and are repressed by 
PRC2 in the ICM40.  This pattern of KDM6B expression was also seen in bovine 
preimplanted embryos, and knockdown of maternal KDM6B mRNA led to impaired 
embryonic development44.  Taken together, these two studies point out the importance of 
KDM6B regulation in the earliest stages of cell lineage commitment, showing it is a 
necessary component for TE development and proper embryonic implantation. 
 Within embryonic stem cells (ESC), the WNT and Nodal/BMP/SMAD signaling 
pathways have been implicated in playing crucial roles in maintaining the balance 
between self-renewal and differentiation45,46.  Experimental evidence suggests that 
KDM6B plays a role in both of these signaling pathways in determining ESC fate 
decisions.  It was shown that in murine (m)ESCs Nodal signaling activates Smads2/3.  
These proteins can directly interact and recruit KDM6B to developmental genes and 
reverse PRC2 silencing.  Interestingly, these genes are only dependent on this pathway 
in the presence of PRC2 indicating that KDM6B plays a specific role in balancing PRC2 
in mESCs47.  While this group showed that KDM6B interacts with Smads2/3 to initiate 
transcription, Teng Fei et al, showed that in mESCs the promoter of Kdm6b is a direct 
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target of BMP4 mediated SMAD1/5 and SMAD4 transcriptional repression.  As 
differentiation begins, SMAD binding at the promoter decreases indicating that the 
repression of KDM6B is necessary for the self-renewal of mESCs48.  In contrast, during 
osteogenic differentiation of human mesenchymal stem cells (hMSC), BMP4 signaling 
increased the expression of KDM6B by SMAD1/4 which in turn activated Hox and 
osteogenic genes49,50.  To add to the complexity, differentiation of hMSCs in odontogenic 
cell lineages required KDM6B to bind to and activate BMP2, a master transcription factor 
of odontogenic genes51.  Taken together, this all suggests that the regulation of KDM6B 
within the Nodal/BMP/SMAD pathway is cell context specific and it can either be 
repressed or serve as a transcriptional activator depending on the cell fate, and in some 
cases may act in a negative-feedback loop.  This is best illustrated in developing spinal 
cord, where hyperactivation of BMP causes SMAD1/4 to recruit KDM6B to the Noggin 
promoter which then allows NOGGIN, the BMP inhibitor, to regulate the increased activity 
of BMP452.  While the regulation of KDM6B by SMAD proteins seems to be unique to 
KDM6B, both UTX and KDM6B were found to be regulators of the WNT signaling pathway 
during endoderm differentiation from human ESCs53 suggesting that there may be 
functional redundancy between the H3K27me3 demethylases in other pathways.  
 While KDM6B functions in gonad development19, MSC differentiation49–51, 
mesodermal and cardiovascular differentiation54,  epidermis55, and retinal bipolar cells56 
have all been described, the role of KDM6B in neural stem cells (NSC) and differentiation 
has been best characterized.  In 2007, the same year KDM6B was identified as a histone 
demethylase, it was shown to play a vital role in retinoic-acid induced mouse forebrain 
development.  Kristin Jepsen et all showed that KDM6B is repressed by SMRT in NSCs 
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and is a direct target of RA-receptor.  When KDM6B expression is increased it in turn 
demethylates and activates the gene expression profile necessary for differentiation57.  In 
agreement with KDM6B being needed for neuronal cell fate, it has been shown that 
KDM6B is more highly expressed in differentiating neural precursors and not self-
renewing ESCs, and KDM6B expression is necessary for neural commitment.  
Interestingly, KDM6B role in neuronal cell fate seemed to be acting in both a demethylase-
dependent and independent manner.  Neural regulators such as Nestin, Pax6, and Sox6 
gene expression depends on KDM6B expression.  All showed increased expression as 
neuronal differentiation occurred but Nestin showed decreased H3K27me3 levels at the 
promoter and Pax6 and Sox1 had increased H3K27me3 levels at their promoters58.  
Though this seems counterintuitive, it was shown that while the role of KDM6B in neuronal 
differentiation from ESCs is dependent on its demethylase activity, it is not dependent 
upon the presence or maintenance of H3K27me352. As previously discussed, it is possible 
that KDM6B histone demethylase-independent role in NSC differentiation is a result of its 
influence on p53 subcellular localization in NSCs, and the demethylation of p53 and 
localization to the nucleus may contribute to gene expression changes that do not affect 
the H3K27me3 levels38.   
In addition to being essential in the neuronal development from ESCs, KDM6B has 
also been shown to play a critical role in adult NSCs.  KDM6B was found to be required 
for neuron survival in the hippocampus after pilocarpine-induced seizures in adult mice59.  
It was found that in post-mitotic cerebellar granule neurons, KDM6B is required to induce 
a gene signature that is required for synapse maturation60.  In addition to this, ablation of 
KDM6B in the adult subventricular zone results in impaired differentiation of adult NSCs61.  
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While the all of these studies were conducted in vitro, constitutive knockout of KDM6B 
using a gene trap method in mice resulted in perinatal death due to respiratory failure, 
however lung development and cardiac rhythm was unaffected.  Further analysis of the 
knockout mice indicated that loss of KDM6B disrupts the Bötzinger complex of the 
respiratory rhythm generator in the brain62.  Surprisingly, the anticipated effects that 
KDM6B would have on preimplantation, embryogenesis, and neuronal development were 
not seen in this study, or another study using a neomycin-cassette to replace exons 14-
21 of Kdm6b to create a germline knockout mouse63, indicating that in vitro analysis of 
KDM6B function may not correlate with in vivo outcomes. 
1.4 KDM6B Regulates Transcription in a Demethylase-
Independent Manner 
 While KDM6B has been shown demethylate both histones and other proteins, and 
its role in development seems mainly reliant upon its demethylation activity, accumulating 
evidence also suggests that KDM6B also regulates transcription by demethylase-
independent mechanisms.  Using a double UTX-KDM6B knockout mouse model, it was 
seen that this genetic combination was embryonic lethal in females but the catalytically 
inactive UTY was capable of rescuing male mice.  This suggests that these proteins may 
play a role in development beyond that of demethylation, or there are additional proteins 
acting in this pathway64.  Evidence also suggests that KDM6B plays a role in DNA damage 
response.  In ESCs inhibition of KDM6B by the small molecule inhibitor GSK-J4 led to an 
increase in γH2AX65.  However, GSK-J4 has been shown to inhibit both UTX and 
KDM6B28, indicating that the results seen in this study may not be directly due to inhibition 
of KDM6B.  However, Kristine Williams et al, showed that upon irradiation, p53 recruits 
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KDM6B to its targeted promoters of genes involved in cell cycle response to stress and 
apoptosis.  Furthermore, no detectable decrease in H3K27me3 was observed66.  While 
p53 bound promoters have been shown to have decreases in H3K27me367, it was not 
observed in this study indicating a possible demethylase-independent role.   
 During cellular reprogramming of mouse embryonic fibroblasts to induced pluripotent 
stem cells, KDM6B has also been shown to interact with TRIM26, recruiting it to target 
protein PHF20 for ubiquitination and subsequent degradation and thus inhibiting cellular 
reprogramming. Both wild-type and catalytically inactive KDM6B are capable of bridging 
this interaction between TRIM26 and PHF20 indicating that it is not dependent upon its 
demethylation activity68.  Another protein that KDM6B has been shown to interact with is 
the T-box factor, T-bet, to alter chromatin architecture.  In differentiating T-helper 1 (Th1) 
cells, KDM6B was shown to be necessary for Ifng, Ccl3, and Cxcr3 to be expressed, and 
catalytically-inactive KDM6B was capable of eliciting these transcriptional responses with 
the exception of Ccl369.  Further analysis showed that KDM6B physically interacts with 
SWI/SNF remodeling complex and allows it to interact with T-bet acting as a bridge69.  
The interaction between KDM6B and the SWI/SNF complex was not dependent on T-bet 
and occurred in unstimulated cells indicating KDM6B may play a role in remodeling 
chromatin architecture in other contexts69.  In addition to remodeling chromatin structure 
to make promoters more accessible, KDM6B has also been shown to influence 
transcriptional elongation.  In 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced 
macrophage-like differentiation of HL-60 cells, chromatin-immunoprecipitation (ChIP) and 
gene expression data suggested that KDM6B acts in both demethylase-dependent and 
–independent ways70.  Data suggests that KDM6B aids in the assembly of full-length 
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mRNAs and it does so by recruiting elongation factors SPT6 and SPT16 to its target 
genes and releases RNA Pol II70.  Taken together, the data from these studies suggests 
that along with being a histone and protein demethylase, KDM6B is capable of interacting 
with proteins, aiding in protein localization, recruiting protein-protein interactions, bridging 
the interaction between chromatin remodeling complexes and transcription factors, and 
increasing transcriptional elongation. 
1.5 KDM6B as a Regulator of Inflammatory Response 
 Many studies have identified KDM6B as an inflammatory and stress response 
gene to a variety of stimuli.  One of the first groups to identify KDM6B as a H3K27-
demethylase did so in the context of macrophages in response to bacterial exposure. 
Francesca De Santa et al showed that upon stimulation of macrophages with 
lipopolysaccharide (LPS), Kdm6b gene expression increases immediately after exposure, 
and the expression is induced by NF-κB binding to two  consensus sites in the first 
intron27.  This paper provided evidence of two promoters for KDM6B: one that is active in 
ESCs and one that is active in macrophages27.  They saw that HoxA genes as well as 
Bmp2 were targets of KDM6B and their expressions were demethylase-dependent.  
Additionally, this study provided evidence that upon inflammatory stimuli, newly transcribe 
KDM6B proteins associate with MLL- complexes27.  Previously, it had been shown that 
UTX also associates with MLL- complexes71, however, it should be noted that in this 
context only Kdm6b, and not Utx, increased in expression upon LPS stimulation27.  
Follow-up studies by the same group, however, had surprising results, whereas in the 
first study they found examples of KDM6B demethylating Bmp2, ChIP-SEQ showed no 
difference in H3K27me3 peaks before or after LPS-stimulation in macrophages. In fact, 
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KDM6B was found to be bound to genes that had the activating H3K4me3 marker and 
transcriptionally active RNA Pol II.  73% of bound KDM6B genes had increased RNA Pol 
II activity post-LPS stimulation. Additionally, they were able to show that when H3K27me3 
was lost, it was due to the loss of nucleosomes and not demethylation72.  Of note, fetal-
liver derived macrophages from Kdm6b-KO mice showed no differentiation defects and 
very few gene expression changes, however, they did show in a subset of genes, loss of 
KDM6B results in reduced RNA Pol II recruitment72.  While these studies provided direct 
evidence of NF-κB controlling Kdm6b expression, another study has shown that ablating 
KDM6B in THP-1 cells not only led to a 2-fold decrease in NF-κB signaling pathway 
proteins, but also in the ablation of NF-κB itself73, indicating that the expression of these 
two proteins is tightly linked, and a possible regulatory feedback loop may exist. 
 A key component to innate immunity is the polarization of macrophages into M1 or 
M2 cells depending on the stimuli74–76. The polarization into M1 macrophages supports a 
pro-inflammatory response and typically involves IFNγ activation77,78, whereas the 
polarization into M2 macrophages promotes anti-inflammatory responses and is activated 
by IL-4 and IL-1376,79.  In a study to identify key components in macrophage response to 
IFNγ or IL-4, it was shown that Kdm6b expression increases after treatment of either of 
these stimuli indicating it has an important role in the polarization of macrophages80.  
While differentiation into macrophages did not seem to be affected by loss of KDM6B72, 
polarization of M2 macrophages, but not M1, required Kdm6b in a demethylase-
dependent manner.  Takashi Satoh et al, found that in response to chitin or helminth 
infection, Kdm6b-KO M2 macrophages are made in equal numbers but fail to recruit 
eosinophils.  While H3K27me3 levels did not correlate to differences in gene expression 
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between wild-type and Kdm6b-KO macrophages, polarization of M2 macrophages was 
reliant upon the expression of transcription factor Irf4, which could only be rescued by 
ectopic expression of wild-type KDM6B and not catalytically inactive KDM6B63.   The 
reliance of KDM6B for M2 polarization was further explored in microglia.  In microglia it 
was shown that suppression of KDM6B inhibited M2 polarization81, similar to what was 
previously shown in macrophages63.  In contrast to the previous study, however, they 
found that the inhibition of M2 polarization led to an increase in the M1 inflammatory 
responses and subsequent neuron death81.  Possibly linking KDM6B to Parkinson’s 
disease, KDM6B regulation of neuronal development, inflammation, and aging, they also 
found that in aged mice KDM6B expression in the midbrain is lower than that of young 
mice, and as a result there is an increased ratio of M1 to M2 polarized macrophages81.  
Taken together, this suggests that KDM6B plays a vital role in both the pro- and anti-
inflammatory pathways, and loss of KDM6B prevents M2 macrophages from acting in an 
anti-inflammatory manor, while potentially promoting the pro-inflammatory effects of M1 
macrophages.  Given that polarization of M1 macrophages was unaffected by loss of 
KDM6B, but that it has been shown to be a direct target of M1 polarizing stimuli, it may 
suggest that in M1 macrophages, KDM6B may work to suppress the pro-inflammatory 
pathways post-stimulus.   
Further characterizing the role of KDM6B in LPS activated microglia, another group 
showed that the increase in KDM6B expression is reliant on the expression of both STAT1 
and STAT3, and in the absence of both of these proteins, KDM6B cannot activate the 
inflammatory gene expression signature82.  This is interesting, because in glioblastoma 
stem cells, STAT3 inhibits KDM6B expression to promote self-renewal83, but in the 
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presence of inflammatory stimuli in microglia, it is necessary for KDM6B activation, 
indicating once again the importance of cellular context on KDM6B regulation.  In addition 
to being a target of primary stimuli such as LPS, INFγ, and IL-4, KDM6B was also shown 
to be upregulated by serum amyloid A (SAA)84, which is a biproduct of inflammatory tissue 
in response to inflammatory stimuli85,86.  This suggests that regardless of the pathway 
KDM6B is a key component to macrophage response signatures.  Foam cell 
macrophages play an important role in atherosclerotic lesion formation and have been 
shown to exhibit an M2 polarization anti-inflammatory signature87.  Interestingly, loss of 
KDM6B in foam cells led to a reduction in the pro-fibrotic gene signature88 indicating that 
KDM6B may control other pathways in M2 macrophages beyond the anti-inflammatory 
gene signature.   
KDM6B plays vital roles in immune response of cells beyond macrophages.  As 
previously discussed, KDM6B plays a crucial role in the differentiation of naïve CD4+ T-
cells into Th1 cells.  This transition requires the expression of Ifng, and conversely this 
expression needs to be sequestered in order to Th2 cell differentiation89.  The 
demethylase-independent interaction between KDM6B, T-BET, and the SWI/SNF 
complex was required in order to ensure chromatin accessibility of the Ifng locus and 
subsequent transcription69.  This also points to the fact that KDM6B not only increases in 
expression in response to INFγ in macrophages, but is responsible for its expression in 
TH1 cells which are responsible for providing the IFNγ signal to activate macrophages.  
Interestingly, inhibition of KDM6B in a mouse experimental autoimmune 
encephalomyelitis (EAE) model,  led to reduced severity of disease and increased the 
production of Treg cells and not the pro-inflammatory TH1 or TH17 cells, but this was 
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found to be regulated by its effect on dendritic cells (DC), and not on the T-cells90.  Beyond 
affecting how T-cells differentiate or respond to environmental cues, KDM6B has also 
shown to be crucial for the thymic egression of CD4+ cells, and loss of KDM6B leads to 
an accumulation of CD4+ in the thymus and a reduction in splenic CD4+ cells, however, 
this function of KDM6B was shown to be redundant with UTX91.  Given its role in immunity 
it comes as no surprise that KDM6B has been shown several times that to be induced 
after viral infections92,93. While the role of KDM6B in macrophages and the immune 
system has been studied extensively, it has also been shown to be upregulated during 
amino acid deprivation94 and under hypoxic conditions95 indicating that it is a key 
component to cellular stress responses beyond inflammation. 
1.6 KDM6B as a Tumor Suppressor 
 Epigenetic modifiers are frequently mutated or dysregulated in malignancies, and 
therefore often studied as potential therapeutic targets.  KDM6B is no exception, however, 
unlike many epigenetic modifiers, the effects of KDM6B in different malignancies have 
been widely variable.  In many cancers, KDM6B has been identified as a tumor 
suppressor.   In non-small cell lung cancer (NSCLC) cell growth correlated with KDM6B 
expression levels, with the lowest expression conferring to the fastest growth.  It was 
shown that overexpressing KDM6B in NSCLC cells led to apoptosis.  Further mechanistic 
studies showed that KDM6B interacts with FOXO1, an inducer of apoptosis.  
Overexpression of KDM6B leads to decreased phosphorylation of FOXO1 and relocation 
into the nucleus96.  Overexpression of KDM6B in glioblastoma stem cells leads to 
decreased neurosphere formation which are associated with poor patient prognosis97, 
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and as previously discussed it was shown that in glioblastoma cells KDM6B is inhibited 
by STAT3, which maintains the self-renewal of the glioblastoma stem cells83.  Another 
group additionally showed that in glioblastoma stem cells KDM6B acts as a tumor 
suppressor via its ability to control p53 cellular localization, and increased KDM6B 
expression led to increased accumulation of p53 in the nucleus98.  In pancreatic ductal 
adenocarcinoma (PDAC), there is frequently a loss of heterozygousity of KDM6B99.  
Analysis of expression of KDM6B in normal pancreatic ducts compared to both PDAC 
and the precursor lesions pancreatic intraepithelial neoplasms (PanIN) indicated that as 
disease progresses KDM6B expression decreases100.  Further, knockdown of KDM6B in 
PDAC cells led to increased cell growth and when transplanted into xenographic mice 
showed reduced survival due to the decreased expression of the tumor suppressor 
CEBPα100.  Analysis  Vitamin D has been identified as a potential therapy101,102 for several 
cancers, including colon.  Fábio Pereira et al, showed that when colon cancer cells are 
treated with the active vitamin D metabolite 1α,25-dihydroxyvitamin D3, KDM6B 
expression was increased, and furthermore, was necessary for the induction of vitamin D 
target genes which act to prevent epithelial-mesenchymal transition (EMT).  Additionally, 
they saw that in patient colon cancer cells Kdm6b and vitamin D receptor (Vdr) gene 
expression had a strong correlation103.   
Possibly the most extensively studied mechanism of tumor suppression by KDM6B 
is its role in oncogenic induced senescence (OIS) via the regulation of INK4A/ARF locus.  
It has been shown that KDM6B is a direct regulator of OIS.  KDM6B increases in 
expression following RAS or RAF oncogenic exposure in human fibroblasts which leads 
to reduction in EZH2 levels104, as well as the increased expression of the OIS regulator 
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p16INK4A 104,105.  This increase in p16INK4A protein is dependent upon KDM6B demethylase 
activity, and further the increase of KDM6B expression is activated via the macrophage 
promoter of KDM6B104,105.  In colorectal cancer, KDM6B expression leads to an increase 
in p15INK4B, and in patient samples these two proteins expression levesl are highly 
correlated with low expression of either of these proteins being a poor prognostic factor 
in patients106.  In addition to controlling the INK4A/ARF locus, KDM6B has also been 
shown to be critical in the formation of senescence-associated heterochromatin foci 
(SAHF) due to its interaction with and demethylation of retinoblastoma (pRB) protein at 
K81068,107.  Taken together, these studies suggest that KDM6B can play a role as a tumor 
suppressor through multiple different mechanisms of action. 
1.7 KDM6B as an Oncogene 
 Indicating the importance of cellular context in conjunction with KDM6B, there have 
also been numerous studies that indicate KDM6B plays a role as an oncogene.  Perhaps 
most surprisingly, in human papillomavirus E7 (HPV-E7) oncoprotein induced cervical 
carcinomas, KDM6B is highly expressed and in turn increases p16INK4A protein108.  
However, because HPV-E7 also simultaneously degrades pRB109, this activation does 
not lead to OIS.  HPV-E7 cervical cells are dependent upon KDM6B and have been 
termed “KDM6B addicted”.  Further, they also show addiction to the downstream p16INK4A  
110, indicating that the very same pathway in which KDM6B acts as a tumor suppressor 
in many different cancers, can also make it a oncogene in the right cellular context.  
Epstein-Barr virus (EBV) is another oncogenic virus that is associated with Burkitt’s and 
Hodgkin’s lymphoma, was shown to upregulate the expression of KDM6B, and it is 
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hypothesized that KDM6B contributes to the pathogenesis of this malignancy as well92.  
Supporting this hypothesis, KDM6B also shows high expression in diffuse large B-cell 
lymphoma (DLBCL), and inhibition of KDM6B induced apoptosis and increased sensitivity 
of DLBCL cells to chemotherapy agents111.   
 In breast cancer, KDM6B has been shown to act as an oncogene in several ways.  
It was shown that in anti-oestrogen (AE) sensitive breast cancer cells, KDM6B 
demethylates the enhancer of the anti-apoptotic BCL2 gene, and loss of KDM6B 
subsequently leads to an increase in apoptosis112.  While in colon cancer, KDM6B was 
shown to act as a tumor suppressor by preventing EMT after vitamin D treatment103, in 
breast cancer cells, KDM6B has been shown to be necessary for breast carcinoma 
invasion113.  KDM6B expression increased in more invasive breast cancers, and it was 
shown that KDM6B is required for TGF-β EMT113.  It should be noted that overexpression 
of KDM6B is not always indicative of a good therapeutic target, as it was shown in pleural 
mesothelioma that inhibition of KDM6B induced a cytokine storm which would be 
detrimental to the normal tissue114. 
1.8 KDM6B in Hematopoietic Malignancies 
 While UTX and other epigenetic modifiers are frequently mutated in hematopoietic 
malignancies115–118, mutations in KDM6B are rare in blood cancers.  In fact, only one 
study in a rare CD4+ mature T-cell leukemia, Sézary syndrome, did find that 47.5% of 
patients harbored 17p13.1 deletions that included KDM6B, but only one was predicted to 
be deleterious, and an additional 16.7% of patients had mutations including one 
frameshift119.  The role KDM6B plays on CD4+ T-cell development may explain the finding 
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that KDM6B is mutated or deleted in this cancer, but found to be overexpressed in T-cell 
acute lymphoblastic leukemia (T-ALL)120, multiple myeloma (MM)121, and myelodysplastic 
syndrome (MDS)122 but not frequently mutated.  In NOTCH1-driven T-ALL, it was shown 
that KDM6B may play an oncogenic role120.  Interestingly, in both MM and MDS, reducing 
KDM6B expression resulted in changes in immune signaling121,122, indicating that KDM6B 
may be playing a role in stress response in hematopoietic malignancies.  MSCs lack 
immunogenicity51, however, hematopoietic stem cells (HSCs) and their progenitors 
express immune receptors123, so it stands to reason that KDM6B may be required for 
immune and stress response in these cells.  While bone marrow transplants (BMT) of 
fetal liver cells of Kdm6b-KO did not show any deficits in the peripheral blood63,120, other 
epigenetic modifiers have been shown to have differing roles in fetal versus adult 
hematopoiesis124.   
Our study aimed to elucidate the role KDM6B plays in normal adult 
hematopoiesis and its effect on proliferative and oncogenic stress in hematopoiesis.  
We found that contrary to what was seen in fetal livers, KDM6B is required for adult 
HSC self-renewal and the maintenance of the stem cell compartment, and it plays a 
vital role in quiescence and stress response to a variety of stimuli.  Moreover, we show 
that KDM6B serves an oncogenic function in adult acute myeloid leukemia as genetic 
inhibition results in increased latency to AML and a reduced self-renewal of leukemia-
initiating cells in an MLL-AF9 model.  Taken together, our results suggest that KDM6B 
mutations are not common in hematopoietic cancers because this protein is essential 
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2.1 Introduction 
KDM6B, also known as JMJD3, is one of two known epigenetic modifiers 
responsible for enzymatic removal of the repressive histone H3 lysine 27 trimethylation 
(H3K27me3) mark18,19,22,25,26.  This modification is associated with transcriptional 
repression and gene silencing6,126.  Removal of H3K27me3 by either KDM6B or KDM6A 
(UTX1) is required for lineage-specific gene expression and differentiation in embryonic 
stem cells19,26,55,58.  In addition, KDM6B has been shown to play a role in stress response 
in macrophages27,28,72, hippocampal neurons59, and fibroblasts104,105.  The role of KDM6B 
in the inflammatory response is not redundant with UTX1, and evidence suggests that 
KDM6B may have demethylase-independent functions in response to stress72,121. 
Genome sequencing of hematopoietic malignancies has identified recurrent 
somatic mutations in many epigenetic modifiers115–117.  While mutations in KDM6A are 
found in blood cancers such as acute myeloid leukemia (AML), KDM6B mutations have 
not been identified117,118. In contrast, gene expression analysis has found that KDM6B is 
over-expressed in a range of blood disorders including myelodysplastic syndromes 
(MDS)122, Hodgkin’s lymphoma (HL)92, multiple myeloma (MM)121, and T-cell acute 
lymphoblastic leukemia (T-ALL)120. In NOTCH1-driven T-ALL, it was shown that while 
UTX1 acts as a tumor suppressor120,127, KDM6B plays an oncogenic role120.  These data 
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may suggest that KDM6B is necessary for hematopoiesis and aberrant expression is a 
contributing factor in blood cancers.  Germline deletion in mice of Kdm6b led to perinatal 
lethality due to incomplete respiratory development, however transplantation of fetal liver 
cells did not show a defect in hematopoietic development63,120.  To date, the role of 
KDM6B in hematopoietic stem cell (HSC) biology has not been studied in adult 
hematopoiesis. Given that Kdm6b is upregulated in numerous adult hematopoietic 
malignancies, and that other epigenetic modifiers have been shown to have differing roles 
in embryonic and adult hematopoiesis124, we developed a conditional loss-of-function 
mouse model to study the role of Kdm6b in hematopoietic development and HSC fate 
decisions in adult mice. We show that loss of Kdm6b leads to a significant reduction in 
phenotypic and functional HSCs, which increases with age, and is required for self-
renewal of leukemia-initiating cells in AML. Additionally, we show that loss of Kdm6b 
leads to the inability for HSCs to respond to proliferative stress signals, resulting in 
defective self-renewal and a differentiation cascade leading to the inability to maintain the 
HSC compartment. 
2.2 Results 
2.2.1 Loss of Kdm6b results in depletion of phenotypic hematopoietic 
stem cells 
To study the role of Kdm6b in hematopoiesis, a conditional knockout mouse was 
generated by crossing the Vav-CRE driver128 to delete floxed exons 14-20 of Kdm6b129 
in hematopoietic cells128. Complete floxed allele recombination was observed in 
phenotypically-defined hematopoietic stem cells (HSCs; Lineage- Sca-1+ c-Kit+ CD48- 
CD150+ EPCR+, Supplementary Fig. 2.1.1A). In thymocytes, where Kdm6b is highly 
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expressed, we observed complete ablation of Kdm6b protein, but no significant increase 
in global H3K27me3 levels (Supplementary Fig. 2.1.1B,C). Mice were sacrificed at 
eight- and 80-weeks of age for analysis of mature and progenitor populations in blood, 
whole bone marrow (WBM), spleen and thymus. There was a slight reduction in WBM 
cellularity and spleen weight at eight-weeks of age (Supplementary Fig. 2.1.1D,E). Both 
Vav-CRE:Kdm6bfl/+ (Kdm6b-HetVAV) and Vav-CRE:Kdm6bfl/fl (Kdm6b-KOVAV) had a 
significant increase in B-cells and a reduction in myeloid cells compared to control mice 
(Vav-CRE:Kdm6b+/+) in peripheral blood. However, no overt hematological disease was 
observed in mutant mice by 80-weeks of age (Supplementary Fig. 2.1.1F,K). 
HSCs and multipotent progenitors (MPPs; Lineage-, EPCR+, c-Kit+, Sca-1+, CD48- 
CD150-) were analyzed in WBM (Fig. 2.1A). Kdm6b-KOVAV had a 26.77% and 46.61% 
reduction in HSC and MPP frequencies respectively, which when coupled with the 
reduction in WBM cellularity led to a significant reduction in absolute HSC and MPP 
numbers (Fig. 2.1B,C). This depletion of HSCs and MPPs was even greater in aged mice 
(Fig. 2.1D,E).  At eight-weeks of age Kdm6b-HetVAV mice had no difference in HSC or 
MPP frequency or count as compared to controlVAV mice (Fig. 2.1B,C), however, at 80-
weeks of age there was a significant reduction in both HSCs and MPPs, similar to that of 
complete knockout (Fig. 2.1D,E).  This suggests that Kdm6b is an important regulator in 
the aging hematopoietic compartment and older HSCs are more sensitive to dose-
dependent losses of Kdm6b.   We also analyzed WBM for oligopotent progenitors, spleen 
for erythroid progenitors, and thymus for thymic progenitors (Supplementary Fig. 2.1.2A-
O). There was a reduction in myeloid progenitors in old mice, most prominently 
granulocyte/macrophage progenitors (GMPs, Supplementary Fig. 2.1.2C). In 
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agreement with previous studies91, there was an increase in CD4+ and CD8a+ cells in 
the thymus of Kdm6b-KOVAV mice (Supplementary Fig 2.1.2N).   
2.2.2 Loss of Kdm6b results in depletion of functional long-term 
repopulating HSCs 
To determine if the loss of phenotypic HSCs in Kdm6b-KOVAV mice correlated to 
a functional loss of repopulating activity, 2.5 x 105 wild-type WBM cells were 
transplanted into lethally irradiated recipients along with limiting dilution doses of WBM 
from controlVAV, Kdm6b-HetVAV and Kdm6b-KOVAV mice. 16-weeks post-transplant, 
blood chimerism was assessed (Fig. 2.2A, Supplementary Fig. 2.2.1A) and mice were 
classified to have long-term multi-lineage reconstitution (LTMR) if all three blood 
lineages (B-cell, T-cell and myeloid) had >1% engraftment from donor-derived cells (Fig 
2.2B, Supplementary Fig. 2.2.1B,C). The proportion of LTMR mice at each dose was 
used to calculate long-term repopulating cell frequency130. While controlVAV and Kdm6b-
HetVAV mice had a comparable frequency of long-term repopulating cells (1:49,984 and 
1:55,422 respectively), Kdm6b-KOVAV WBM was estimated to have a two-fold reduction 
(1:108,101; p-value 0.054, Fig. 2.2C). In agreement with this observation, there was a 
significant reduction in donor-derived HSCs in Kdm6b-KOVAV recipient mice 18-weeks 
post-transplant (Fig. 2.2D). 
To assess the effect of Kdm6b on self-renewal, 3.0 x 106 WBM from LTMR mice 
was transplanted into secondary recipients. Kdm6b-KOVAV secondary recipients had no 
donor-cell engraftment beyond four-weeks post-transplant (Fig. 2.2E). While overall 
engraftment was equivalent between controlVAV and Kdm6b-HetVAV recipients, only 
37.5% of Kdm6b-HetVAV recipient mice were considered LTMR at the end of secondary 
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transplant as opposed to 83.3% of controlVAV recipients (Fig. 2.2F-G). Post-secondary 
transplant, Kdm6b-HetVAV HSCs were reduced in recipient bone marrow (Fig. 2.2H), 
similar to Kdm6b-KOVAV primary recipient mice, indicating that Kdm6b is necessary for 
HSC self-renewal in a dose-dependent manner. in vitro assay of 1.0 x 104 WBM cells 
recapitulated what was seen in vivo with Kdm6b-HetVAV and Kdm6b-KOVAV WBM having 
reduced colony-forming potential (Fig. 2.2I). 
In aged mice there was an even greater reduction in phenotypic HSCs and MPPs 
in both the Kdm6b-HetVAV and Kdm6b-KOVAV mice.  Because the phenotypic reduction 
observed in eight-week old mice correlated with a functional reduction, 5.0x105 aged 
WBM from controlVAV, Kdm6b-HetVAV and Kdm6b-KOVAV mice was transplanted in a 1:1 
ratio with wild-type WBM into lethally irradiated recipient mice.  There was a significant 
reduction in engraftment of both the Kdm6b-HetVAV and Kdm6b-KOVAV compared to 
controls in a dose-dependent manner (Supplementary Fig. 2.2.2A).  Interestingly, 
Kdm6b-HetVAV recipient mice had equivalent engraftment of myeloid cells 16-weeks 
post-transplant, but a significant reduction in lymphoid lineages, whereas Kdm6b-KOVAV 
recipients had significant reductions in all three lineages (Supplementary Fig. 2.2.2B).  
HSC analysis 18-week post-transplant showed a significant reduction in both Kdm6b-
HetVAV and Kdm6b-KOVAV recipients (Supplementary Fig. 2.2.2C).   
2.2.3 Kdm6b is required for HSC self-renewal 
To more specifically determine the function of Kdm6b in HSC self-renewal, 200 
HSCs from controlVAV, Kdm6b-HetVAV and Kdm6b-KOVAV mice were transplanted with 
2.5 x 105 wild-type WBM competitor cells into lethally irradiated recipients. While donor-
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derived engraftment was comparable at four-weeks post-transplant, subsequent 
timepoints showed a significant decrease in blood chimerism from Kdm6b-KOVAV HSCs 
(Fig. 2.3A), although both Kdm6b-HetVAV and Kdm6b-KOVAV HSCs contributed to all 
three blood lineages (Fig. 2.3B). 18-weeks post-transplant, HSCs from primary 
recipients were resorted and 200 HSCs were transplanted into secondary recipients. 
The significant reduction in donor-derived HSCs (Fig. 2.3C) in Kdm6b-KOVAV primary 
recipient mice limited the number of secondary recipients for this genotype. Secondary 
transplant saw a reduction in donor-derived chimerism in both Kdm6b-HetVAV and 
Kdm6b-KOVAV recipient mice, with myeloid cells comprising the majority their output 
(Fig. 2.3D). The majority of recipient mice of Kdm6b-HetVAV and Kdm6b-KOVAV HSCs 
did not have tri-lineage long-term engraftment (Fig. 2.3E). This may indicate that the 
HSCs remaining post-primary transplant were no longer multipotent, and that Kdm6b is 
necessary for maintenance of lymphoid potential in HSCs. 18-weeks post-secondary 
transplant, there was a significant reduction in donor-derived HSCs in mutant HSC 
recipient mice (Fig. 2.3F), indicating loss of Kdm6b results in compromised self-
renewal. 
2.2.4 Kdm6b is required for self-renewal of leukemia-initiating cells 
To determine if Kdm6b also regulates self-renewal in malignant stem cells, c-Kit 
enriched WBM from controlVAV, Kdm6b-HetVAV and Kdm6b-KOVAV mice was transduced 
with the MLL-AF9 oncogene131, and 1.0 x 105 cells were transplanted into recipient 
mice. Transduction efficiency and frequency of MLL-AF9+ GMPs (the leukemia-initiating 
cells in this model) were comparable between genotypes (Supplementary Fig. 
2.4.1A,B).  Four-weeks post-transplant there was a significant reduction in GFP+ cells 
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in the blood in both Kdm6b-HetVAV and Kdm6b-KOVAV recipient mice (Supplementary 
Fig. 2.4.1C). Notably, no engraftment defect was observed from Kdm6b-HetVAV and 
Kdm6b-KOVAV cells transduced with the control (MIG) retrovirus, suggesting that viral 
transduction is not contributing to the reduced GFP+ blood (Supplementary Fig. 
2.4.1C). The reduction in MLL-AF9-GFP+ blood correlated with a significant increase in 
survival of Kdm6b-HetVAV and Kdm6b-KOVAV transplanted mice compared to controlVAV 
recipients (Fig. 2.4A). There was no difference in spleen weights of moribund mice 
(Supplementary Fig. 2.4.1D), but there was a significant decrease in the number of 
leukemic GMPs in the bone marrow of Kdm6b-HetVAV and Kdm6b-KOVAV recipient mice 
(Fig. 2.4B,C). Secondary transplant was performed with limiting doses of WBM from 
primary MLL-AF9 tumors to determine the frequency of leukemia-initiating cells. 
Recipient mice were scored as positive if they developed AML (Fig. 2.4E), and that 
metric was used to estimate leukemia-initiating cell frequency. Kdm6b-HetVAV and 
Kdm6b-KOVAV tumors had a three-fold reduction in leukemia-initiating cell frequency 
compared to controls (Fig. 2.4F), suggesting Kdm6b also regulates self-renewal of 
leukemia-initiating cells. 
2.2.5 Interferon response and NF-κB signaling are increased in 
Kdm6b-deficient HSCs 
To elucidate potential mechanisms underlying the phenotype of Kdm6b-KOVAV 
HSCs, global transcriptomic analysis was performed. Comparison of gene expression 
profiles of controlVAV and Kdm6b-KOVAV HSCs to identify genes that >2-fold increased or 
decreased expression (adjusted p-value <0.05) found 649 genes that met this criteria 
(Tables 2.1 and 2.2). Surprisingly, 88.3% of these genes showed increased expression 
in Kdm6b-KOVAV HSCs, with only 76 genes having decreased expression (Fig. 2.5A), 
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which was not anticipated following depletion of a protein that removes a repressive 
epigenetic mark. Gene Set Enrichment Analysis (GSEA) was performed to identify 
dysregulated pathways132,133. GSEA identified NF-κB target genes as the gene set most 
significantly upregulated (p-value 0.0, FDR=0.155) in Kdm6b-KOVAV HSCs, in addition 
to interferon response genes (Fig. 2.5B). In macrophages, Kdm6b has been shown to 
become upregulated immediately upon inflammatory stress induced by 
lipopolysaccharide (LPS) and/or interferon gamma (IFNγ) treatment, and has been 
shown to be a direct target of NF-κB28,72. In HSCs, it appears that loss of Kdm6b results 
in expression of a stress-response signature in the native state. 
As Kdm6b has been described as a H3K27me3 histone demethylase, 
ChIPmentation134 for H3K27me3 was performed on controlVAV and Kdm6b-KOVAV 
HSCs. H3K4me3 ChIPmentation was also performed because KDM6B has been shown 
to associate with transcriptionally-activated NF-κB target genes in MDS patients122. 
Principal component analysis (PCA) showed no difference in H3K4me3 between 
controlVAV and Kdm6b-KOVAV HSCs, but a distinct separation in H3K27me3 profiles 
(Supplementary Fig. 2.5.1A). H3K4me3 peaks were highly overlapping between 
genotypes with 99.98% of peaks within 5kB of a transcriptional start site conserved 
(Supplementary Fig. 2.5.1B). H3K27me3 domains showed 67.90% conservation 
between controlVAV and Kdm6b-KOVAV HSCs, with the majority of the differential peaks 
being unique to Kdm6b-KOVAV HSCs (Fig. 2.5C). While there was an increase in the 
number of called H3K27me3 peaks in Kdm6b-KOVAV HSCs (as would be expected 
following depletion of an enzyme that removes H3K27me3), the overall H3K27me3 
pattern was comparable between controlVAV and Kdm6b-KOVAV HSCs (Fig. 2.5D), and 
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H3K27me3 changes did not correlate with altered gene expression (Fig. 2.5E,F, Table 
2.3). Similarly, there was no difference in H3K4me3 patterns (Supplementary Fig. 
2.5.1C-E). Two of the top dysregulated genes in the NF-κB (Fos) and INFγ response 
(Jun) genesets showed no difference in chromatin profile, but a difference in gene 
expression (Fig. 2.5G). Thus, while loss of Kdm6b generates unique H3K27me3 peaks, 
the gene expression differences in Kdm6b-KOVAV HSCs are H3K27me3-independent, 
similar to what is seen in Kdm6b-KO macrophages72. 
2.2.6 Inflammatory stress forces differentiation of Kdm6b-deficient 
HSCs 
To study the role of Kdm6b more specifically in adult HSC maintenance, 
Kdm6bfl/fl mice were crossed to the inducible Mx1-CRE driver135. Mx1-CRE becomes 
active in hematopoietic cells following administration of polyinosinic:polycytidylic (pIpC) 
acid, an immunostiumulant that mimics viral infection and elicits an IFNα response136. 
Mx1-CRE:Kdm6b+/+ (ControlMX1), Mx1-CRE:Kdm6bfl/+ (Kdm6b-HetMX1), and Mx1-
CRE:Kdm6bfl/fl (Kdm6b-KOMX1) mice were treated with six-doses of pIpC and allowed to 
recover for six-weeks. 200 HSCs from controlMX1, Kdm6b-HetMX1 and Kdm6b-KOMX1 
mice were transplanted with 2.5 x 105 wild-type WBM competitor cells into lethally 
irradiated recipients. Kdm6b-KOMX1 HSCs showed a significant reduction in engraftment 
at all timepoints (Fig. 2.6A, Supplementary Fig. 2.6.1A), and a significant reduction in 
Kdm6b-KOMX1 HSCs in the bone marrow of recipient mice (Fig. 2.6). At the time of 
transplant, individual HSCs were concurrently sorted to determine floxing efficiency from 
Mx1-CRE. Surprisingly, 56.9% of HSCs from Kdm6b-KOMX1 mice retained both floxed 
alleles (making them functionally wild-type), and only 22.3% of HSCs had deletion of 
both Kdm6b alleles (Fig. 2.6C). While efficiency of floxed allele recombination in 
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Kdm6b-HetMX1 HSCs was higher, 30.5% of HSCs were still not recombined (Fig. 2.6C). 
To determine if this CRE-deficiency was specific to the Kdm6b allele, we assessed 
floxing efficiency of Utx1 using an Mx1-CRE:Utx1fl/+ (Utx1-HetMX1) mouse model137. 
Using the same pIpC regimen, only 9.1% of the HSCs from these mice were not 
recombined six-weeks post-treatment, indicating that the decreased floxing efficiency is 
likely linked to the biological role of Kdm6b in HSCs (Supplementary Fig. 2.6.1C). 
Because Mx1-CRE is still activated upon bone marrow transplantation138, donor-derived 
HSCs were purified from Kdm6b-HetMX1 recipients at 18-weeks post-transplant to 
determine if floxing efficiency was resolved. There was an increase in deletion efficiency 
post-primary transplant in these HSCs with only 10.8% retaining unrecombined alleles 
(Fig. 2.6C). We were unable to recover any HSCs from Kdm6b-KOMX1 post-transplant to 
assess floxing efficiency. 
Because Kdm6b-HetMX1 HSCs showed efficient floxing post-primary transplant, 
we assessed self-renewal in this model by transplanting 200 donor-derived HSCs from 
controlMX1 and Kdm6b-HetMX1 into secondary recipients. While primary Kdm6b-HetMX1 
recipients only showed a slight reduction in overall engraftment compared to controlMX1 
recipients (Fig. 2.6A), secondary transplantation showed a significant decrease in 
Kdm6b-HetMX1 engraftment (Fig. 2.6D). 16-weeks post-transplant, no Kdm6b-HetMX1 
recipient mice had tri-lineage engraftment (Supplementary Fig. 2.6.1B). 18-weeks 
post-secondary transplant, donor-derived HSCs were almost undetectable in Kdm6b-
HetMX1 recipients (Fig. 2.6E). 
The presence of unrecombined HSCs in Kdm6b-KOMX1 WBM could be a result of 
two possibilities: (A) Mx1-CRE is not efficient in deleting the alleles, or (B) Mx-1-CRE is 
30 
 
efficient, but the recombined HSCs are rapidly outcompeted by the residual 
unrecombined HSCs in the inflammatory environment. To investigate these possibilities, 
200 HSCs from untreated Mx1-CRE:Kdm6b+/+ and Mx1-CRE:Kdm6bfl/fl mice were 
transplanted, allowed to engraft, and then treated with pIpC four-weeks post-transplant. 
Interestingly, even without prior pIpC treatment initial engraftment of Kdm6b-KOMX1 
HSCs was still significantly reduced, which may be due to activation of Mx1-CRE upon 
transplantation into an inflammatory environment post-irradiation (Supplementary Fig. 
2.6.1D). Upon treatment with pIpC, there was a significant reduction in relative 
engraftment in the Kdm6b-KOMX1 recipients (Fig. 2.6F). To determine efficiency of 
floxed allele recombination, granulocytes (Gr-1+, Mac-1+) were purified from WBM of the 
donor mice pre-transplant, and compared to donor-derived macrophages from the blood 
of Kdm6b-KOMX1 recipient mice at eight-weeks post-transplant. RT-PCR of genomic 
DNA indicated that the macrophages in the blood two-weeks post-pIpC were derived 
from efficiently recombined Kdm6b-KOMX1 HSCs as indicated by the significant increase 
in the ratio of deleted allele to the floxed allele (Fig. 2.6G). Two-weeks post-pIpC, there 
was a significant reduction in donor-derived HSCs in the Kdm6b-KOMX1 recipients (Fig. 
2.6H), and functional assay of purified HSCs identified reduced colony-forming potential 
Kdm6b-KOMX1 HSCs (Fig. 2.6I). Surprisingly, of the few colonies that were generated 
from Kdm6b-KOMX1 HSCs, ~90% did show complete recombination of both Kdm6b 
alleles (Supplementary Fig. 2.6.1E). This indicates that pIpC-driven recombination of 
Kdm6b flox alleles using Mx1-CRE is efficient, but that either those HSCs differentiate 
quickly and do not remain in the HSC pool, or are rapidly outcompeted by the residual 
unrecombined HSCs in terms of self-renewal. 
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2.2.7 Kdm6b is necessary for HSC maintenance in response to 
proliferative stress 
To investigate the role of Kdm6b in HSCs under stress conditions without the 
problem of variable floxed allele recombination by Mx1-CRE, controlVAV and Kdm6b-
KOVAV mice were treated with a short course (two doses) of pIpC and analyzed 24-
hours after the second injection. While there was a significant increase in frequency of 
controlVAV HSCs (Lineage- c-Kit+ EPCR+ CD48- CD150+; Sca-1 is excluded because it is 
an IFN-responsive gene) post-pIpC treatment, Kdm6b-KOVAV HSCs showed no change 
in abundance (Figure 2.7A). This increase in controlVAV HSCs was coupled with a 
decrease in quiescence (Figure 2.7B, Supplementary Figure 2.7.1A). While frequency 
of Kdm6b-KOVAV HSCs was unchanged in response to pIpC, there was a significant 
increase in the total progenitor population (Lineage- c-Kit+ EPCR+; Figure 2.7C), 
indicating that upon inflammatory stress, Kdm6b-KOVAV HSCs differentiate to 
downstream progenitors, but fail to self-renew to sustain the HSC pool. Kdm6b-KOVAV 
progenitors were also less proliferative than controls (Figure 2.7D). There was no 
difference in apoptosis (cleaved PARP+) or DNA damage (γH2AX+) in HSCs or 
progenitors from controlVAV or Kdm6b-KOVAV mice post-pIpC exposure (Supplementary 
Figure 2.7.1B-E) providing further evidence that the cause of depletion of Kdm6b-
KOVAV HSCs under inflammatory stress is commitment to terminal differentiation and 
not mechanisms (e.g. increased apoptosis) that would render the mutant HSCs less 
competitive.  
The failure of Kdm6b-KOVAV HSCs to exit quiescence after pIpC treatment led us 
to compare gene expression in Kdm6b-KOVAV HSCs with a HSC quiescence geneset 
signature139. There was significant overlap between these genesets (Figure 2.7E), with 
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all of the shared genes having increased expression in Kdm6b-KOVAV HSCs. 
Furthermore, four of these overlapping genes were the top dysregulated NF-κB target 
genes (Figure 2.7F). This may indicate that Kdm6b-KOVAV HSCs have altered cell cycle 
kinetics in response to proliferative stress due the inability to silence genes associated 
with HSC quiescence.  
To test the ability of Kdm6b-mutant HSCs to regenerate the hematopoietic 
system after proliferative stress, controlVAV, Kdm6b-HetVAV and Kdm6b-KOVAV mice 
were injected with 5-flurouracil (5-FU) which kills rapidly cycling hematopoietic cells and 
forces quiescent HSCs to proliferate. After a 10-day recovery, there was a slight 
decrease in white blood cell and neutrophil counts (Supplementary Figure 2.7.1F,G), 
but no difference in red blood cell (RBC) or platelet (PLT) counts (Supplementary 
Figure 2.7.1H,I), in Kdm6b-HetVAV and Kdm6b-KOVAV mice, indicating they are capable 
of initial hematopoietic recovery. However, upon serial 5-FU injection, both Kdm6b-
HetVAV and Kdm6b-KOVAV mice had a significant decrease in survival compared to 
controlVAV mice (Figure 2.7G). Interestingly, the loss of Kdm6b does not seem to be 
dose dependent under these conditions, unlike bone marrow transplantation but 
analogous to challenge with MLL-AF9 oncogenic stress (Figure 2.4A). To examine 
HSC kinetics acutely after myeloablative stress, controlVAV, Kdm6b-HetVAV and Kdm6b-
KOVAV mice were treated with one dose of 5-FU and assessed for HSC (Lineage- Sca-
1+ EPCR+ CD150+ CD48-; c-Kit is excluded from these analyses as it is downregulated 
upon 5-FU treatment) frequency and cell cycle. There was no discernable difference in 
HSC frequency between any of the groups (Figure 2.7H), but an increase in the 
proportion of quiescent (G0) HSCs at both day two and day six post-5FU treatment in 
33 
 
Kdm6b-KOVAV HSCs (Figure 2.7I), as well as the total progenitor population (Lineage- 
Sca-1+ EPCR+; Supplementary Figure 2.7.1J,K). HSC quiescence genes (Fos, Dusp1, 
Zfp36, and Ier2) that were over-expressed in Kdm6b-KOVAV HSCs became further 
upregulated after treatment with pIpC (Figure 2.7j). Post-5-FU treatment, there was also 
a significant increase in these genes two-days post-treatment compared to controlVAV 
HSCs, however six-days post-5-FU treatment, the expression of these genes 
normalized (Figure 2.7K). As a control, we showed Gata2 (a gene identified in the HSC 
quiescence signature and an NF-κB target gene that is not dysregulated in Kdm6b-
KOVAV HSCs) did not increase post-treatment with either pIpC (Supplemental Figure 
2.7.2A) or 5-FU (Supplemental Figure 2.7.2B) in Kdm6b-KOVAV HSCs, indicating that 
Kdm6b regulates a specific subset of genes involved in this response. One HSC gene 
upregulated in Kdm6b-KOVAV HSCs, Fos, associates with Jun to form the AP1 
transcription factor complex, and loss of AP1 has been associated with differentiation 
block140–142. Additionally, chronic overexpression of Fos in HSCs was shown to 
decrease colony forming potential and increase dormancy of HSCs143.  Like Fos, Jun is 
upregulated in Kdm6b-KOVAV HSCs at baseline and increases further after pIpC 
(Supplementary Figure 2.7.2C) and 5-FU (Supplemental Figure 2.7.2D). As loss of 
the AP1 complex inhibits differentiation, over-expression of this complex may promote 
differentiation of Kdm6b-KOVAV HSCs over self-renewal after they have exited 
quiescence. 
2.3 Summary 
Unlike many epigenetic modifiers, including KDM6A, KDM6B is not frequently 
mutated in hematopoietic malignancies. Here, we show that loss of Kdm6b 
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compromises self-renewal of both normal and leukemic stem cells. In transplantation, 
Kdm6b is necessary for HSC self-renewal in a dose dependent manner. These results 
suggest that KDM6B mutations are not observed in hematopoietic malignancies as 
even corruption of one allele in a HSC would result in the eventual loss of that clone due 
to a competitive disadvantage against wild-type HSCs. 
Our data suggests that the major roles of Kdm6b in HSCs are not directly related 
to histone demethylase activity, but rather demethylase-independent regulation of stress 
response gene expression programs. Upon proliferative stress, Kdm6b-deficient HSCs 
do not self-renew, but rather differentiate rapidly to more committed downstream 
progenitors (Fig. 2.8). This could be in part due to the increased expression of the AP1 
transcription factor complex subunits, Jun and Fos. Previous studies have shown that 
AP1 inhibition has been shown to increase cellular proliferation and inhibit 
differentiation142, thus perhaps increased AP1 activity in Kdm6b-deficient HSCs leads to 
increased quiescence and a differentiation push when the mutant HSCs finally engage 
cell cycle similar to the phenotype that is seen when Fos is overexpressed in HSCs143. 
One of the hallmarks of aging HSCs is a skewing toward myeloid lineages144 and 
a weakening of immune response145.  We observed that in aged mice, loss of Kdm6b 
seems affect both heterozygous and homozygous knock-out mice in phenotypic HSC 
and MPPs equally. Further, in eight-week old transplanted WBM and HSCs, a 
difference between controlVAV and Kdm6b-HetVAV engraftment and HSCs were not 
observed until secondary transplant, but in aged WBM transplantation the phenotype 
was observed in the primary transplant.  The HSCs that were remaining in Kdm6b-
HetVAV recipients had a decreased lymphoid, but comparable myeloid contribution as 
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compared to controlVAV recipients.  The ability to contribute to the myeloid lineage and 
less so to the lymphoid was also seen in secondary HSC transplants form eight-week 
old donors of both Kdm6b-HetVAV and Kdm6b-KOVAV recipients.  Given the inflammatory 
signature of Kdm6b-KOVAV HSCs as well as the myeloid skewing we observed, the 
phenotype associated with loss of Kdm6b is very similar to that of aged HSCs, 
suggesting Kdm6b plays an important role in the stem cell fate decisions of young 
HSCs. 
Loss of Kdm6b in MLL-AF9-driven AML significantly increases survival and 
decreases self-renewal of leukemia-initiating cells, presenting KDM6B as a novel 
therapeutic target for hematopoietic malignancies. GSK-J4, a small molecule inhibitor of 
KDM6B and KDM6A, has been widely cited as a potential therapeutic agent for a variety 
of blood cancers28,120. GSK-J4 binds to the catalytic domain and inhibits demethylase 
activity of both KDM6B and KDM6A. Our data suggests that therapeutic agents 
targeting the demethylase activity of KDM6B would likely be ineffective, and that more 
specific effects could be achieved by development of small molecules targeting the 
domains which regulate its unique functions in HSCs. Additionally, therapeutic inhibition 
of KDM6B may be improved by combination with chemotherapies that induce HSC 
differentiation, as blocking KDM6B activity would lead to an inability of the leukemia-







2.4.1 Mice  
All animal procedures were approved by the Institutional Animal Care and Use 
Committee and performed in strict adherence to Washington University School of 
Medicine institutional guidelines. All mice used in this study were the C57Bl/6 
background. Kdm6bfl/fl mice129 were kindly provided by Dr. Martin Matzuk (Baylor 
College of Medicine) and backcrossed to the C57Bl/6 background (The Jackson 
Laboratory strain # 000664) for over five generations. Kdm6bfl/fl mice were crossed to 
Mx1-CRE135 or Vav-CRE128 strains to generate hematopoietic conditional knockout 
mice. Utx1fl/fl mice137 were kindly provided by Dr. Lukas Wartman (Washington 
University). Six doses (300 μg/mouse) of polyinosinic:polycytidylic acid (pIpC, Sigma 
#p1530) spaced in 48-hour intervals were administered via intraperitoneal (IP) injections 
into Mx1-CRE mice to induce recombination of floxed alleles. Genotyping primers are 
found listed in Table 2.4. 
2.4.2 Bone Marrow Transplantation 
C57Bl/6 CD45.1 (The Jackson Laboratory strain # 002014) mice were used as 
recipients for bone marrow transplantation. For competitive transplantation, recipient 
mice were given a split dose (~4-hours apart) of lethal irradiation totaling 10.5 Gy prior 
to transplantation via retro-orbital injection. For MLL-AF9 secondary transplants, 
recipient mice were given a single dose of 6.0 Gy sublethal irradiation. For limiting 
dilution transplants, either 2.0x104, 5.0x104, or 1.0x105 whole bone marrow (WBM) from 
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CD45.2 donor mice was transplanted along with 2.5 x105 CD45.1 wild-type WBM cells 
into lethally irradiated recipients. Secondary WBM transplants of the limiting dilution 
recipients were performed by transplanting 3.0x106 WBM cells from individual primary 
recipients into secondary lethally irradiated mice.  
For hematopoietic stem cell (HSC) transplantation, 200 donor HSCs (CD45.2+, 
Lineage-, c-Kit+, Sca1+, CD48-, and CD150+) were purified by flow cytometry and 
transplanted along with 2.5 x105 CD45.1 wild-type WBM cells into lethally irradiated 
recipients. Secondary HSC transplants were established by re-purifying 200 donor-
derived HSCs from primary recipients and transferring to secondary lethally irradiated 
recipient mice along with fresh wild-type WBM competitor.  
For MLL-AF9 transplants, 1.0x105 c-Kit enriched WBM cells were transduced 
with MLL-AF9 retrovirus and transplanted into lethally irradiated recipient mice. For 
secondary transplantation, either 1x103 leukemic GMPs (CD45.2+, GFP+, Lineage-, c-
Kit+, Sca1-, CD16/32+, CD34+ cells), or 5x103, 1.5x104 or 5.0x104 WBM cells from 
individual tumors were transplanted into sublethally irradiated recipients.  
Bone marrow chimeras were established by transplanting 2.5x105 donor WBM 
with 2.5x105 CD45.1 wild-type WBM cells into lethally irradiated recipients. The blood of 
transplanted recipient’s was analyzed to assess donor-cell contribution every four-
weeks by retro-orbital bleeding and flow cytometry.  
2.4.3 Flow Cytometry 
Flow cytometry panels used for phenotypic identification of hematopoietic cell 
populations used in this study are found in Table 2.5. Cell sorting and analysis was 
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performed at the Siteman Cancer Center flow cytometry core and the Washington 
University Department of Pathology and Immunology flow cytometry core. 
All antibody staining was done at a cell density of 7.0x107 in 100uL of complete 
Hanks Balanced Salt Solution (HBSS, Corning #21021CV) containing Pen/Strep 
(100Units/mL, Fisher Scientific #MT30002CI), HEPES (10μM, Life Technologies 
#15630080) and Serum Plus II (2%, Sigma #14009C). Samples were incubated on ice 
for 20 minutes with the appropriate antibodies (Table 2.6).  
WBM (tibias, femurs, and iliac crests), spleen and thymus were harvested and 
analyzed for analysis of stated cell populations in Table 2.5. Magnetic enrichment of 
WBM was used prior to HSC purification by flow cytometry and retroviral transduction. 
WBM was incubated on ice with mouse CD117-conjugated microbeads (Miltenyi Biotec 
#130-091-224) and the samples were enriched using the AutoMACS Pro Separator 
(Miltenyi Biotec #130-092-545). Following enrichment, the c-Kit+ fraction was stained 
with appropriate antibodies for flow cytometry. For transplant recipients, donor-cell 
versus wild-type competitor contribution to blood was distinguished using the different 
CD45 isoforms (CD45.2 vs. CD45.1 respectively). Lineage contribution was determined 
by assessing myeloid (Gr-1+ and Mac-1+), B-cell (B220+) and T-cell (CD3e+) 
populations. 
For intracellular flow cytometry, samples were stained for surface markers 
overnight at 4°C. Samples were fixed and permeabilized using the Cytofix/Cytoperm 
Fixation/Permeabilization Kit (BD Biosciences #554714), then stained in the dark in a 
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total of 50μL with intracellular antibodies (PARP, γH2AX, KI67) for 20 minutes at room 
temperature. 
2.4.4 Western Blotting 
For Kdm6b western blots, total nuclear protein extract was isolated from 2.0x107 
thymocytes using Nuclear Extract Kit (Active Motif #40010). 50μg of sample was loaded 
into pre-casted 4-15% gradient SDS gels (Biorad #456-1084) and transferred to 
nitrocellulose membranes (Millipore #IPVH00010). Membranes were probed with 
Kdm6b antibody (Cell Signaling #3457), or Hdac2 (Cell Signaling #2540) and were 
detected using horseradish-peroxidase-conjugated secondary rabbit antibody (GE 
Healthcare #NA9340) and chemiluminescence HRP substrate (Millipore #WBKLS0100). 
2.4.5 H3K27me3 quantification 
Total histones from 1.0x107 thymocytes were extracted using the EpiQuik Total 
Histone Extraction Kit (EpiGentek # OP-0006-100). H3K27me3 quantification from 
these extracts was determined using EpiQuik Global Tri-Methyl Histone H3K27 
Quantification Kit (Colorimetric) (EpiGentek #P-3042-96). Input per sample was 50ng, 
and absorbance was read using the Epoch Microplate Spectrophotometer (BioTek). 
2.4.6 LPS, pIpC, and 5-FU injections 
Lipopolysaccharide (LPS) (Sigma Aldrich #L2880) was administered at a dose of 
1ug/mouse via IP injections daily for 30 days. 5-fluorouracil (5-FU, Sigma Aldrich 
#F6627) was administered at a dose of 150mg/kg via IP injection. To assess initial 
recovery, mice were given a single 5-FU dose and allowed ten days for hematopoietic 
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regeneration. Following this dose, mice were given serial injections at seven-day 
intervals until morbidity or the end of experiment. For short-term stress response to 
pIpC, mice were given two 300ug doses of pIpC 48-hours apart via IP injection and 
analyzed 24-hours after the last injection. 
2.4.7 Methocult Plating 
Colony forming potential was assessed by plating 1.0x104 WBM cells into a 6-
well plate with 2mL of methocellulose-based medium (MethCultTM GF M3434, Stemcell 
Technologies #03434). Cells were given nine-days and then colonies were counted. 
Floxing efficiency was checked by sorting single HSCs into 96-well plates containing 
MethoCultTM GF M3434 and allowed two-weeks to grow. Individual colonies were 
collected and washed with Dulbecco’s Phosphate Buffered Saline (Sigma #D8537), and 
genomic DNA was isolated using the KAPA Express Extract Kit (Sigma # KK7103). 
2.4.8 Plasmids and Viral Transduction 
pMSCV-IRES-GFP-MLL-AF9 (pMIG-MLL-AF9) retroviral plasmid was kindly 
provided by Dr. Jeff Magee (Washington University). For retroviral production, 293T 
(ATCC #CRL-3216) cells were co-transfected with retroviral packaging vector (pCL-
Eco) and either empty vector control (pMIG-GFP) or pMIG-MLL-AF9 using 
lipofectamine 3000 (ThermoFisher Scientific #L3000008). Supernatents were collected 
48-hours post-transfection and stored at -80°C until transduction.  
For retroviral transduction, 1.0x106 cells/500uL were plated in Stempro-34 
medium (Gibco #10639011) supplemented with Pen-Strep (100 Units/mL), L-glutamine 
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(2 mM), murine stem cell factor (100 ng/mL), murine thrombopoietin (100ng/mL), murine 
Flt3L (50ng/mL), murine interleukin-3 (5 ng/mL), and polybrene (4 mg/mL; Sigma), and 
spin-fected in 48-well tissue culture plates (CytoOne #CC7682-7548) with retrovirus 
supernatant at 250g for two-hours on consecutive days. 
2.4.9 Quantitative Real-Time PCR 
Total RNA was isolated using the NucleoSpin RNA XS kit (Macherey-Nagel 
#740902.250) and converted to cDNA with the SuperScript VILO kit (Invitrogen #11754-
050). Real-time PCR was performed on the StepOnePlus RealTime PCR System (Life 
Technologies), using a mix of standardized cDNA, Taqman Master Mix (Applied 
Biosystems #4304437), 18s rRNA probe (VIC-MGB; Applied Biosystems #74319413E), 
and a gene-specific probe (FAM-MGB; Applied Biosystems, see table below). Samples 
were normalized to 18s and fold-change was determined by the ΔΔCT method.  Gene-
specific probes are found in Table 2.7. 
To assess efficiency of floxed allele recombination in Mx1-CRE:Kdm6bfl/fl 
transplant recipient mice post-pIpC treatment, macrophages (Mac-1+, Gr-1+) were 
sorted and gDNA was made using the PureLink Genomic DNA mini kit (Invitrogen 
#K1820-02). Real-time PCR was performed on the StepOnePlus RealTime PCR 
System (Life Technologies), using a standardized mix of gDNA, PowerSYBR Green 
PCR master mix (AppliedBiosystems #4367659), and the universal forward primer with 
either the WT/Floxed or deleted reverse primer. Samples were normalized to GAPDH 




2.4.10 RNA-SEQ data, quality control and analysis 
HSCs were purified from three biological replicates (composed of pooled WBM 
from three male and three female mice) of either ControlVAV or Kdm6b-KOVAV mice. 
Total RNA was isolated using the NucleoSpin RNA XS kit (Macherey-Nagel 
#740902.250). Library preparation, sequencing, and alignment was performed by the 
Genome Technology Access Center (Washington University). The SMARTer Ultra Low 
RNA kit (Clontech) was used to prepare the libraries from 3-5ng of total RNA. 
Sequencing was performed with an Illumina HiSeq-3000. RNA-seq reads were aligned 
to the Ensembl release 76 top-level assembly with STAR version 2.0.4b146. Gene 
counts were derived from the number of uniquely aligned unambiguous reads by 
Subread:featureCount version 1.4.5147,148. Transcript counts were produced by Sailfish 
version 0.6.3149. Sequencing performance was assessed for total number of aligned 
reads, total number of uniquely aligned reads, genes and transcripts detected, 
ribosomal fraction known junction saturation and read distribution over known gene 
models with RSeQC version 2.3150,151. 
Aligned reads were imported into Partek® Genomics Suite® software, verision 
6.6 Copyright ©; 2016 (Parek Inc., St. Louis, USA) for statistical analysis. Quantification 
and normalization of gene RPKM was performed with an expectation maximization 
algorithm (EM) using the mouse mm10 genome. Principal component analysis (PCA) 
was used to check for sample outliers. Differential expression analysis using ANOVA 
was performed assigning each gene a p-value, and a differentially expressed gene list 
was generated using the conditions p<0.05 and a fold-change of >2.0 in Kdm6b-KOVAV 
HSCs as compared to controlVAV (Table 2.1 and 2.2). Gene set enrichment analysis 
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(GSEA)132,133 was performed using expression data to identify genesets that were 
dysregulated in Kdm6b-KOVAV HSCs. Primary RNA-SEQ data is available under GEO 
accession number GSE110378. 
2.4.11 ChIPmentation 
ChIPmentation was performed as previously described134.  Briefly, 1.0x104 HSCs 
were sorted into PBS+10% FBS, and then crosslinked at room temperature for 8-
minutes using 1% paraformaldehyde (VWR #J531). Chromatin was sheared using a 
Covaris E220 Focused-ultrasonicator until the DNA fragments were between 200 – 700 
base pairs. Chromatin samples were incubated overnight at 4°C with either the 
H3K27me3 antibody (Diagenode #pAb-069-050) or the H3K4me3 antibody (Diagenode 
#pAb-003-050). Following overnight incubation, protein G dynabeads (Life Technologies 
#130-099-508) were added for 2-hours at 4°C. The beads were washed, and tagmented 
for 10-minutes at 37°C using the Nextera DNA Library Preperation Kit (Illumina #FC-
121-1030). After additional washes, an overnight decrosslinking was performed and 
immunoprecipiated DNA was isolated using Ampure XP beads (Beckman Coulter 
#NC9959336). 2xKapa HiFi HotStart Ready Mix (Kapa #KB KK2601), along with 
Nextera custom primers, was used for library amplification of the ChIP DNA (12 cycles 
of PCR as determined by qPCR). Libraries were again purified with Ampure XP beads 
and run on an Illumina Hiseq 3000 (PE2X150). 
Sequences were aligned to mm10 using Bowtie2152. Peak calling of H3K27me3 
and H3K4me3 was performed with hiddenDomains153, the R package ChIPQC154 was 
used for quality control including PCA plots. HOMER plots for H3K27me3 and 
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H3K4me3 were made using deepTools155. BEDOPS156 was used to determine 
overlapping and unique H3K27me3 and H3K4me3 regions between Kdm6b-KOVAV 
HSCs and controlVAV HSCs. Primary ChIPmentation data is available under GEO 
accession number GSE110378.  
2.4.12 Statistics 
GraphPad Prism Version 6 (GraphPad Software Inc.) was used for statistics and 
graphing of data. Student t-test, one-way, and two-way ANOVA’s were used for 
statistical comparisons where appropriate. Survival curves were analyzed using a 


















Figure 2.1: Loss of Kdm6b results in depletion of phenotypic 
hematopoietic stem cells. 
(A) Flow cytometry gating scheme to identify hematopoietic stem cells (HSCs) and 
multipotent progenitors (MPPs) in whole bone marrow (WBM) of eight-week old 
ControlVAV (top) or Kdm6b-KOVAV mice (bottom). (B) Frequency of HSCs and MPPs in 
WBM of eight-week old ControlVAV (CNT, n=14), Kdm6b-HetVAV (HET, n=18), and Kdm6b-
KOVAV (KO, n=16) mice (C) Absolute number of HSCs and MPPs in WBM of eight-week 
old ControlVAV (CNT, n=14), Kdm6b-HetVAV (HET, n=18), and Kdm6b-KOVAV (KO, n=16) 
mice. (D) Frequency of HSCs and MPPs in WBM of 80-week old ControlVAV (CNT, n=12), 
Kdm6b-HetVAV (HET, n=9), and Kdm6b-KOVAV (KO, n=14) mice. (E) Absolute number of 
HSCs and MPPs in WBM of 80-week old ControlVAV (CNT, n=12), Kdm6b-HetVAV (HET, 
n=9), and Kdm6b-KOVAV (KO, n=14) mice. Mean ± S.E.M. values are shown. *p<0.05, 




















Supplementary Figure 2.1.1: Loss of Kdm6b does not generate 
hematopoietic malignancies. 
(A) PCR showing complete recombination of Kdm6b floxed alleles in single HSCs from 
ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice. (B) Kdm6b protein expression by 
western blot in thymocytes from ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice. (C) 
Colorimetric assay quantifying H3K27me3 levels in thymocytes from ControlVAV, Kdm6b-
HetVAV, and Kdm6b-KOVAV mice (n=7). (D) WBM cellularity of ControlVAV (n=14), Kdm6b-
Het (n=18), and Kdm6b-KOVAV mice (n=16) at eight-weeks of age. (E) Spleen weights of 
ControlVAV (n=11), Kdm6b-Het (n=15), and Kdm6b-KOVAV mice (n=13) at eight-weeks of 
age. (F) Tri-lineage analysis of blood from ControlVAV (n=11), Kdm6b-Het (n=15), and 
Kdm6b-KOVAV mice (n=13) at eight-weeks of age. Blood counts of (G) white blood cells 
(WBC), (H) neutrophils (NE), (I) red blood cells (RBC), (J) hemoglobin (Hb), and (K) 
platelets (PLT) from ControlVAV (n=13), Kdm6b-Het (n=9), and Kdm6b-KOVAV (n=14) mice 













Supplementary Figure 2.1.2: Progenitor analysis in young and aged 
Kdm6b-deficient mice. 
(A) Flow cytometry gating scheme for myeloid progenitors from WBM. Frequency of 
myeloid progenitors in eight-week (B) and 80-week (C) ControlVAV, Kdm6b-HetVAV, and 
Kdm6b-KOVAV mice (B, n=11, 15, 13; C, n=12, 9, 14 respectively). (D) Flow cytometry 
gating scheme for lymphoid progenitors from WBM. Frequency of lymphoid progenitors 
in eight-week (E) and 80-week (F) ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice 
(E, n=11, 15, 13; F, n=4, 9, 14 respectively). (G) Flow cytometry gating scheme for B-cell 
progenitors from WBM. Frequency of B-cell progenitors eight-week (H) and 80-week (I) 
ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice (H, n=11, 15, 13; I, ControlVAV, 
Kdm6b-HetVAV, and Kdm6b-KOVAV mice.=4, 9, 14 respectively). (J) Flow cytometry gating 
scheme for erythrocyte progenitors from spleen. Frequency of spleen erythrocyte 
progenitors eight-week (K) and 80-week (L) ControlVAV, Kdm6b-HetVAV, and Kdm6b-
KOVAV mice (H, n=11, 15, 13; I, n=12, 9, 14 respectively). (M) Flow cytometry gating 
scheme for mature thymocytes and thymic progenitor cells. (N) Frequency of mature 
thymocytes in eight-week old ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice (n=18, 
15, 18 respectively). (O) Frequency of thymic progenitors in eight-week old ControlVAV, 
Kdm6b-HetVAV, and Kdm6b-KOVAV mice (n=18, 15, 18 respectively). Mean ± S.E.M. 











Figure 2.2: Loss of Kdm6b results in depletion of functional long-term 
repopulating HSCs.  
 
(A) Donor-derived chimerism in B-cell, Myeloid and T-cell blood populations16-weeks 
post-transplant in mice transplanted with 20K, 50K, and 100K WBM cells from ControlVAV, 
Kdm6b-HetVAV, and Kdm6b-KOVAV (n=9-10) mice. (B) Proportion of long-term multi-
lineage reconstituted (LTMR) recipient mice at each cell dose 16-weeks post-transplant. 
(C) Frequency of long-term repopulating cells using a maximum likelihood estimate with 
extreme limiting dilution analysis (ELDA) software. (D) Frequency of donor-derived 
(CD45.2+) HSCs in WBM of recipient mice 18-weeks post-transplant. (E) Peripheral 
blood engraftment in secondary transplants of 3.0x106 WBM from LTMR primary recipient 
mice. (F) Donor-derived chimerism in B-cell, Myeloid and T-cell blood populations 16-
weeks post-transplant in secondary recipient mice. (G) Proportion of LTMR secondary 
recipient mice transplanted with ControlVAV (n=6), Kdm6b-HetVAV (n=8), and Kdm6b-
KOVAV (n=6) primary WBM. (H) Frequency of donor-derived HSCs in WBM of secondary 
recipient mice 18-weeks post-transplant. (I) Number of colonies formed from 1x104 WBM 








Supplementary Figure 2.2.1: Blood analysis to establish long-term 
multilineage reconstitution (LTMR).  
 
(A) Flow cytometry gating scheme for analysis of blood trilineages (Myeloid: Mac-1+, Gr-
1+, B-cells: B220+, and T-cells: CD3e+). (B) Representative flow cytometry plots of donor 
derived engraftment of all three lineages from a recipient mouse scored as LTMR. (C) 
Representative flow cytometry plots of donor derived engraftment of all three lineages 






Supplementary Figure 2.2.2: WBM from aged mice shows depletion of 
functional repopulating HSCs. 
 
(A) Peripheral blood engraftment of primary recipients from transplantation of 5.0x105 WBM 
from aged mice from ControlVAV (n=3), Kdm6b-HetVAV (n=4), and Kdm6b-KOVAV (n=3) mice. (B) 
Donor chimerism in B-cell, Myeloid and T-cell blood populations at 16-weeks post-transplant in 
recipient mice. (C) Frequency of donor-derived HSCs in WBM of recipient mice 18-weeks post-













Figure 2.3: Kdm6b is required for HSC self-renewal  
(A) Peripheral blood engraftment of primary recipients from transplantation of 200 HSCs from 
ControlVAV (n=10), Kdm6b-HetVAV (n=9), and Kdm6b-KOVAV (n=9) mice. (B) Donor chimerism in 
B-cell, Myeloid and T-cell blood populations at 16-weeks post-transplant in recipient mice. (C) 
Frequency of donor-derived HSCs in WBM of recipient mice 18-weeks post-transplant. (D) 
Peripheral blood engraftment of secondary recipients transplanted with 200 HSCs from 
ControlVAV (n=9), Kdm6b-HetVAV (n=9), and Kdm6b-KOVAV (n=4) primary recipient mice. (E) 
Donor chimerism in B-cell, Myeloid and T-cell blood populations at 16-weeks post-transplant in 
secondary recipient mice. (F) Frequency of donor-derived HSCs in WBM of secondary recipient 























Figure 2.4: Kdm6b is required for self-renewal of leukemia-initiating 
cells.  
 
(A) Kaplan-Meier survival curve comparing time to morbidity between recipient mice 
transplanted with ControlVAV (n=8), Kdm6b-HetVAV (n=7), and Kdm6b-KOVAV (n=6) c-Kit+ 
WBM cells transduced with the MLL-AF9 oncogene. (B) Flow cytometry gating scheme 
showing leukemic-initiating cells (GFP+ GMPs) in ControlVAV (top) and Kdm6b-KOVAV 
(bottom) recipient mouse WBM. (C) Frequency and (D) absolute number of leukemic 
GMPs in WBM of moribund recipient mice. (E) Secondary limiting dilution transplantation 
response and (F) leukemic stem cell frequency estimates as calculated by a maximum 
likelihood estimate using extreme limiting dilution analysis (ELDA) software. Mean ± 

















Supplementary Figure 2.4.1: Kdm6b is required for self-renewal of 
leukemia-initiating cells.  
 
(A) Representative transduction efficiency from one experimental replicate showing 
frequency of GFP+ GMPs (Lin-, c-Kit+, Sca-1-, CD16-32+, CD34-) in c-Kit enriched 
ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV cells three-days post-transduction with 
empty vector (pMIG) control, or pMIG-MLL-AF9 retroviruses. (B) Representative number 
of GFP+ GMPs transplanted per 100K cells post-transduction. (C) Percentage of GFP+ 
blood cells four-weeks post-transplant. (D) Spleen weights from moribund primary MLL-









Figure 2.5: Interferon response and NF-κB signaling are increased in 
Kdm6b-deficient HSCs.  
 
(A) Hierarchical clustering of genes with >2-fold increased or decreased expression 
(adjusted p-value <0.05) in Kdm6b-KOVAV HSCs compared to ControlVAV HSCs. (B) Gene 
Set Enrichment Analysis (GSEA) showing upregulation of NF-κB and interferon gamma 
response genes in Kdm6b-KOVAV HSCs. (C) Venn diagram showing H3K27me3 domains 
overlapping >10% the transcriptional start site (TSS) ± 5kB. (D) Homer plot of H3K27me3 
distribution ± 5Kb from transcriptional start sites (TSS) in all genes. (E) Homer plot of 
H3K27me3 distribution ± 5Kb from TSS in 573 genes that have > 2-fold increased 
expression in Kdm6b-KOVAV HSCs. (F) Homer plot of H3K27me3 distribution in 76 genes 
that have > 2-fold decreased expression Kdm6b-KOVAV HSCs. (G) H3K27me3 and 
H3K4me3 profiles (left) and RNA-seq expression values (right) of Fos and Jun showing 
no correlation between chromatin prolfile and gene expression. Statistics were calculated 















Supplementary Figure 2.5.1: Chromatin profile of Kdm6b-deficient HSCs  
 
(A) Principal component analysis (PCA) of H3K27me3 and H3K4me3 ChIPmentation profiles 
between ControlVAV and Kdm6b-KOVAV HSCs. (B) Venn diagram showing H3K4me3 domains 
overlapping >10% the transcriptional start site (TSS) ± 5kB. (C) Homer plot of H3K4me3 
distribution ± 5Kb from transcriptional start sites (TSS) in all genes. (D) Homer plot of H3K4me3 
distribution ± 5Kb from TSS in 573 genes with >2-fold increased expression in Kdm6b-KOVAV 









Figure 2.6: Inflammatory stress forces differentiation of Kdm6b-
deficient HSCs without self-renewal.  
 
(A) Peripheral blood engraftment of primary recipients transplanted with 200 HSCs from 
ControlMX1 (n=9), Kdm6b-Het MX1 (n=10), and Kdm6b-KO MX1 (n=5) mice. (B) Frequency 
of donor-derived HSCs in WBM of primary recipient mice at 18-weeks post-transplant. 
(C) Efficiency of Mx1-CRE driven floxed allele recombination in HSCs from mice six-
weeks post-pIpC treatment, as well as post-primary transplant in Kdm6b-Het MX1 HSCs. 
(D) Peripheral blood engraftment of secondary recipients transplanted with 200 HSCs 
purified from primary recipient mice of Control MX1 (n=9) and Kdm6b-HetMX1 (n=11) HSCs. 
(E) Frequency of donor-derived HSCs in WBM of secondary recipient mice 18-weeks 
post-transplant. (F) Relative peripheral blood chimerism of recipients transplanted with 
200 ControlMX1 and Kdm6b-KOMX1 HSCs treated with pIpC four-weeks post-transplant 
(n=5). (G) Floxed allele recombination efficiency in macrophages from donors (pre-) and 
eight-week recipients (post-) pIpC treatment. (H) HSC frequency eight-weeks post-
transplant (two-weeks post-pIpC treatment). (I) Colony-forming potential of HSCs purified 
from recipient mice two-weeks post-pIpC treatment. Mean ± S.E.M. values are shown. 























Supplementary Figure 2.6.1: Inflammatory stress forces differentiation 
of Kdm6b-deficient HSCs.  
 
(A) Donor chimerism in B-cell, Myeloid and T-cell blood populations at 16-weeks post-
transplant in primary recipient mice. (B) Donor chimerism in B-cell, Myeloid and T-cell 
blood populations at 16-weeks post-transplant in secondary recipient mice. (C) Floxed 
allele recombination efficiency in Utx1-HetMX1 HSCs six-weeks post-pIpC treatment. (D) 
Donor-cell engraftment in peripheral blood pre- and two-weeks post-pIpC treatment. (E) 
Floxed allele recombination efficiency in individual Kdm6b-KOMX1 HSCs two-weeks 





















Figure 2.7: Kdm6b is necessary for HSC maintenance in response to 
proliferative stress  
 
(A) HSC frequency in WBM after two doses of either PBS (control) or pIpC in ControlVAV and 
Kdm6b-KOVAV mice (n=7). (B) Proportion of quiescent HSCs (G0) after two doses of either PBS 
(control) or pIpC in ControlVAV and Kdm6b-KOVAVmice (n=7). (C) Progenitor (Lineage- c-Kit+ 
EPCR+) frequency in WBM after two doses of either PBS (control) or pIpC in ControlVAV and 
Kdm6b-KOVAV mice (n=7). (D) Proportion of quiescent progenitors (G0) after two doses of either 
PBS (control) or pIpC in ControlVAV and Kdm6b-KOVAV mice (n=7). (E) Overlap between genes 
with >two-fold increased or decreased expression with the Q-sig geneset previously identified. 
(F) NF-κB target genes with increased enrichment in Kdm6b-KOVAV HSCs compared to 
ControlVAV HSCs identified by GSEA with Q-sig genes highlighted in red. (G) Kaplan-Meier 
survival curve comparing time to morbidity of ControlVAV (n=8), Kdm6b-HetVAV (n=8), and 
Kdm6b-KOVAV (n=8) mice after serial 5-FU treatment. (H) HSC frequency in mice at day 0 
(ControlVAV (n=11), Kdm6b-HetVAV (n=9), and Kdm6b-KOVAV (n=8)), two-days post-5FU 
treatment (ControlVAV (n=8), Kdm6b-HetVAV (n=4), and Kdm6b-KOVAV (n=10)), and six-days 
post-5FU treatment (ControlVAV (n=12), Kdm6b-HetVAV (n=6), and Kdm6b-KOVAV (n=9)). (I) 
Proportion of quiescent HSCs (G0) at day 0, two-days post-5FU treatment and six-days post-
5FU treatment. (J) Expression of genes involved in HSC quiescence after PBS (control) or two-
doses of pIpC in ControlVAV HSCs (n=3) and Kdm6b-KOVAVHSCs (n=3). (K) Expression of 
genes involved in HSC quiescence at baseline, two-days post-FU treatment, and six-days post-
5FU treatment in ControlVAV HSCs (n=3, 3, and 5 respectively) and Kdm6b-KOVAV HSCs (n=3, 


















Supplementary Figure 2.7.1: Kdm6b is necessary for HSC 
maintenance in response to proliferative stress.  
 
(A) Flow cytometry gating scheme showing cell cycle analysis of HSCs from controlVAV and 
Kdm6b-KOVAV mice after PBS (control) or pIpC treatment. (B) Frequency of HSCs after PBS 
(control) or pIpC treatment undergoing apoptosis as measured by flow cytometric analysis of 
cleaved PARP. (C) Frequency of HSCs after PBS (control) or pIpC treatment with DNA damage 
response measured by flow cytometric analysis of γH2AX. (D) Frequency of progenitors after 
PBS (control) or pIpC treatment undergoing apoptosis measured by cleaved PARP. (E) 
Frequency of progenitors after PBS (control) or pIpC treatment with DNA damage response as 
measured by γH2AX. (F-I) White blood cell (WBC), neutrophil (NE), red blood cell (RBC) and 
platelet (PLT) counts in blood of ControlVAV (n=7), Kdm6b-HetVAV (n=9), and Kdm6b-KOVAV 
(n=8) mice pre- and ten-days post-5-FU treatment. (J) Progenitor frequency in ControlVAV, 
Kdm6b-HetVAV, and Kdm6b-KOVAV mice 0, 2 and 6 days post-5-FU treatment. (K) Proportion 
ControlVAV, Kdm6b-HetVAV, and Kdm6b-KOVAV mice progenitors in G0 0, 2 and 6 days post-5-FU 















Supplementary Figure 2.7.2: Kdm6b is necessary to resolve 
expression of quiescence genes in HSCs  
 
Expression profile of Gata2 (a HSC quiescence signature gene not dysregulated in Kdm6b-
KOVAV HSCs) in HSCs after (A) pIpC and (B) 5-FU treatment. Expression profile of AP1 



















Figure 2.8 Kdm6b-deficient HSCs do not self-renew but rapidly 
differentiate more committed downstream progenitors 
 
Schematic representation comparing HSC fate decisions between controlVAV and 




































Table 2.1 Downregulated Genes in Kdm6b-KOVAV HSCs (>2-Fold 















Gm8787 0.0625153 0.002609574 0.0205955 0.00170373 3.03539 0.000176732 
2610507I01Rik 3.709333333 0.273591534 0.333587667 0.126721616 11.1195 0.000362367 
Stxbp4 8.193396667 0.444633279 2.64112 0.227602304 3.10224 0.000372685 
Ifit1bl1 1.89126 0.095795652 0.542378667 0.090378337 3.48697 0.000512282 
Fndc9 0.061063733 0.003567587 0.0149676 0.003060886 4.07972 0.000606212 
Lyrm7 1.273056667 0.020061187 0.464409333 0.091587182 2.74124 0.000993587 
Synb 0.173734667 0.007252308 0.0483917 0.012970179 3.59017 0.00108192 
Ypel4 0.136412 0.0137285 0.0175782 0.009334824 7.76028 0.00201603 
Sh2d4a 0.774908 0.04397443 0.265330667 0.058810189 2.92054 0.00226474 
1700125H03Rik 0.125205333 0.004431483 0.015784067 0.015784067 7.93239 0.00261916 
Tbx4 0.113468 0.008595302 0.0186842 0.011688843 6.07293 0.00283647 
0610043K17Rik 0.669269667 0.060223082 0.164948567 0.057754824 4.05745 0.00377982 
A430085M09Rik 0.030123667 0.00393977 0.002432273 0.002432273 12.385 0.00392851 
Med1 77.7309 11.46255012 14.18326667 1.06108486 5.48047 0.00525759 
Gria3 2.244773333 0.171749515 1.075127333 0.130168561 2.08791 0.00558899 
Rbm44 0.449686 0.043701075 0.165152667 0.032546649 2.72285 0.00641948 
Gid4 8.94939 0.834536543 4.093176667 0.410474898 2.18641 0.00642023 
Gm6981 0.311463667 0.032827862 0.104230133 0.023528216 2.98824 0.00683386 
Sbspon 0.068623033 0.010607216 0.009503133 0.005089289 7.22109 0.00735895 
Pla2g4c 0.499078333 0.043776061 0.196707667 0.041425795 2.53716 0.0074012 
Pnpla1 0.0235867 0.004043493 0.001778907 0.001778907 13.2591 0.00783542 
Cd300lb 0.190883 0.027536319 0.02397316 0.021300369 7.96237 0.0086832 
Sema3c 0.010351363 0.001041775 0.001609453 0.001609453 6.43159 0.0103409 
Nfia 30.99433333 3.331932319 15.10153333 1.037050287 2.05239 0.0103833 
Spon2 0.392404667 0.046513566 0.069692667 0.056610442 5.63051 0.0116501 
Rgs5 0.100181467 0.01008393 0.03161517 0.012941909 3.16878 0.0139276 
75 
 
Hist1h3g 0.1068421 0.010349625 0.0186386 0.0186386 5.7323 0.0144085 
Cpa3 2.230573333 0.263061518 1.107607333 0.08819844 2.01387 0.0155089 
Gm16793 0.101256467 0.023708539 0.004615067 0.004615067 21.9404 0.0161149 
Rtl1 0.014205933 0.001725633 0.003945157 0.001973302 3.60086 0.0173314 
Gm5779 1.313494333 0.301672018 0.125683767 0.034242789 10.4508 0.0173601 
Nostrin 0.129872633 0.026423942 0.018865233 0.011509181 6.88423 0.0182786 
Slc25a48 0.0538266 0.001905037 0.017433 0.009336044 3.08763 0.0187867 
Gm15217 0.062120833 0.01205899 0.0077804 0.0077804 7.98429 0.019327 
Zfp454 0.136019267 0.02842107 0.0187109 0.01332312 7.26952 0.020169 
Cxcr6 0.131213133 0.03381617 0.005369733 0.005369733 24.4356 0.0212905 
Slamf7 0.018416 0.004111653 0.00200524 0.00200524 9.18394 0.0230156 
BC100451 0.055572633 0.014078295 0.004031767 0.004031767 13.7837 0.0244603 
0610039H22Rik 2.908743333 0.733257609 0.319729 0.065045531 9.09754 0.0245157 
4930447C04Rik 1.98163 0.254706146 0.899117 0.175559475 2.20398 0.0249105 
Ermap 1.932366667 0.241866792 0.441870467 0.352349977 4.37315 0.0251786 
Fpr2 0.257661333 0.01994297 0.055381 0.055381 4.65254 0.0263778 
Kel 0.609217 0.050961991 0.185932 0.113625439 3.27656 0.0273013 
Pde6a 0.047875233 0.013473344 0.001899677 0.001899677 25.2018 0.0278135 
Hs6st2 0.0906533 0.009010389 0.03262813 0.014731955 2.77837 0.0283027 
Olfr65 0.1582015 0.03704172 0.018965567 0.018965567 8.34152 0.0286797 
Cmah 0.0320102 0.005129356 0.011518133 0.003365186 2.77912 0.0288266 
Fbxl13 0.048582633 0.013268841 0.003135167 0.003135167 15.496 0.0290151 
Fam46a 1.164166333 0.118018991 0.545954 0.144458296 2.13235 0.0295404 
9530053A07Rik 0.0287659 0.007879747 0.00201334 0.00201334 14.2876 0.030232 
Nxpe4 0.410090667 0.070279798 0.16575 0.024305342 2.47415 0.0303369 
Adgre1 0.205100667 0.035484517 0.088387733 0.002175786 2.32047 0.0304157 
Srsf2 372.7623333 82.952203 101.0621 8.006928465 3.68845 0.0310739 
Tfpi2 0.396758 0.05686394 0.192101 0.026635058 2.06536 0.0311028 
Padi3 0.0197889 0.004183804 0.004320437 0.002290216 4.58031 0.0315802 
Ms4a7 0.359760667 0.079655123 0.0880748 0.028607583 4.08471 0.0325884 
Asb10 0.055912467 0.016562776 0.002345347 0.002345347 23.8397 0.0328307 
Adh1 0.290499667 0.033830917 0.112526567 0.044894368 2.58161 0.0339883 
Nlrp1a 0.276917 0.072696584 0.047135067 0.007384599 5.87497 0.0346922 
Fam186b 0.011172057 0.001191762 0.002502303 0.002502303 4.46471 0.0352513 
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Cacna1h 0.011881393 0.00251815 0.001945737 0.001945737 6.10637 0.0354521 
Dnase1l3 0.1629461 0.03170082 0.0579235 0.011838332 2.81312 0.0360954 
Pparg 0.1884508 0.054908561 0.0190596 0.003897714 9.88744 0.0370316 
Gpr137b-ps 2.90479 0.300259155 1.429075333 0.392639172 2.03264 0.0405162 
Bcas1os2 0.0383534 0.004968781 0.008658367 0.008658367 4.42963 0.0409566 
4930478L05Rik 0.282499 0.065593869 0.074169533 0.02792058 3.80883 0.0431431 
Snca 1.023752667 0.136095366 0.489096667 0.122969671 2.09315 0.0434645 
Samd4 0.026411967 0.008225481 0.00187096 0.00187096 14.1168 0.0437122 
Slc23a1 0.264689 0.037536263 0.128301633 0.028205579 2.06302 0.0439055 
Slc45a3 0.1237583 0.030761967 0.021015013 0.01867203 5.88904 0.0461553 
Slc38a5 1.930573333 0.419890857 0.424688433 0.321632246 4.54587 0.0465319 
C4b 0.050184333 0.009385655 0.0232825 0.001503709 2.15545 0.0473366 
Cpn1 0.1135452 0.035911416 0.008905467 0.008905467 12.7501 0.0474334 
BC024386 0.022060333 0.002353241 0.00819009 0.004349308 2.69354 0.0485723 
Ms4a2 0.277269 0.091727593 0.019438123 0.010094276 14.2642 0.0491127 
Col5a1 0.081283133 0.01544602 0.018294723 0.01651326 4.44299 0.0495281 
 
 
















Dhx40 0.423009333 0.038112613 2.32885 0.064933354 -5.50544 1.45E-05 
Fam129b 0.526887333 0.025050149 1.100636667 0.027990893 -2.08894 0.000107151 
Hdac11 1.136696667 0.087822894 2.49637 0.050737684 -2.19616 0.000179081 
Arhgap33 0.211786667 0.007573768 0.450543 0.01657928 -2.12735 0.000196118 
Dusp22 0.663596333 0.058913528 1.496203333 0.031933264 -2.25468 0.000241256 
Fn3krp 0.274143667 0.162671357 5.974913333 0.43072318 -21.7948 0.000244554 
Cuedc1 0.849794333 0.085633211 3.044526667 0.160026251 -3.58267 0.000268266 
Socs2 4.239186667 0.26446176 10.65152333 0.482315443 -2.51263 0.000309535 
Itm2c 1.78165 0.200374602 4.016836667 0.034421921 -2.25456 0.000389005 
Tspan7 0.161131 0.022997806 0.461752 0.016616453 -2.86569 0.000449063 
Rbm15b 0.155225 0.015909919 0.410896 0.019093522 -2.6471 0.000503593 
Sspo 0.003623643 0.002093997 0.029612033 0.00144427 -8.1719 0.000517252 
Plxnd1 0.186402667 0.018908729 0.645957 0.040984922 -3.46539 0.000524193 
77 
 
Luzp2 0.138562 0.005573331 0.522089667 0.037335201 -3.76792 0.000528484 
Ap5b1 0.173386333 0.013590244 0.411751333 0.019828852 -2.37476 0.000580686 
Zfp128 0.579838333 0.036511193 1.236023333 0.05557202 -2.13167 0.000591529 
Pak6 0.047083633 0.014189519 0.281449 0.019604491 -5.97763 0.000636263 
Per1 0.213605333 0.009746292 0.507551 0.029133254 -2.37612 0.000666498 
Slc39a11 1.975896667 0.082942658 5.289816667 0.336795631 -2.67717 0.000670394 
St6galnac1 0.019672467 0.010416942 0.327104333 0.030530214 -16.6275 0.000676867 
Dlc1 0.012474197 0.002027051 0.0505757 0.003619861 -4.05442 0.000780704 
Wtip 0.076079967 0.009241572 0.166553 0.003806384 -2.18918 0.000825338 
Csf2rb 2.99018 0.16005133 6.095946667 0.314899512 -2.03865 0.000923007 
Plekha4 0.002354907 0.002354907 0.0303155 0.002171206 -12.8733 0.000948794 
Pomgnt2 0.994613667 0.162177122 2.45753 0.044920548 -2.47083 0.000964011 
Gck 0.044946133 0.032163341 0.434841 0.031325607 -9.67469 0.000967839 
Krt8 0.237767667 0.029576367 0.536149 0.018355395 -2.25493 0.00101726 
Wfs1 0.071640533 0.013172799 0.269549 0.019126658 -3.76252 0.00104038 
Nr6a1 0.039062467 0.005754275 0.127193333 0.008738393 -3.25615 0.00108765 
Car5a 0.012598833 0.006671319 0.079600033 0.004532886 -6.31805 0.0011469 
Micall2 0.270215 0.05887593 0.779315667 0.018131338 -2.88406 0.00116987 
Bcam 0.122773467 0.045488369 0.524261 0.017455268 -4.27014 0.00118277 
Epcam 0.136614033 0.019378766 0.451044333 0.033228266 -3.3016 0.00121966 
Syde1 0.907371 0.139814052 2.14734 0.066423543 -2.36656 0.00131721 
Pgm5 0.00196536 0.001040695 0.014033033 0.001106306 -7.1402 0.00135893 
Dnaic1 0.068953367 0.007379507 0.155675333 0.008149661 -2.25769 0.00139682 
Zfp579 0.245830667 0.020755417 0.503108667 0.026075007 -2.04657 0.00151582 
Klhl42 1.443076667 0.272586963 6.23846 0.566197733 -4.32303 0.0015836 
Npr2 0.953658333 0.07238169 1.910726667 0.102612102 -2.00358 0.00159097 
Itgb4 0.070140167 0.009772283 0.249964667 0.021578727 -3.56379 0.00161529 
Ctxn1 0.701444 0.099402266 1.611633333 0.069617289 -2.29759 0.00169075 
Lrrc32 0.004924567 0.004924567 0.0533145 0.004309865 -10.8262 0.0017839 
Ccser1 0.0404276 0.006019116 0.115578 0.008194017 -2.85888 0.00178654 
AA465934 7.857686667 2.248747162 31.4181 2.267592579 -3.9984 0.00179932 
C330021F23Ri
k 
0.0259831 0.015389617 0.172857 0.012929679 -6.65266 0.00186551 
Dxo 0.868801 0.096456703 1.778396667 0.079279127 -2.04696 0.00188671 
Fscn1 0.368342667 0.022702516 0.828328 0.060461284 -2.2488 0.00205415 
Zdhhc8 0.126728933 0.019343547 0.342570333 0.023821438 -2.70317 0.00215285 
Pdxk-ps 0.096995867 0.018642683 0.287435667 0.020004751 -2.96338 0.0022344 
Sytl1 0.604414 0.179648086 2.101663333 0.118171666 -3.47719 0.00223616 
2810428I15Rik 4.463186667 0.921483427 11.11383333 0.287765485 -2.49012 0.00232701 
Cdh10 0.001968153 0.001968153 0.0388466 0.005037695 -19.7376 0.00241841 
Crtc2 2.243013333 0.394312397 5.3521 0.233791346 -2.38612 0.00246704 
Plppr3 1.967716667 0.38590679 5.25195 0.293871712 -2.66906 0.0024828 
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Ager 0.104496467 0.025846439 0.303088333 0.013888568 -2.90046 0.00248628 
1700037C18Ri
k 
0.138370233 0.032551995 0.461256 0.035118412 -3.33349 0.00252117 
Pacrgl 1.155256 0.157160799 2.620743333 0.151716877 -2.26854 0.00256945 
BC029722 0.887579 0.198667403 2.300916667 0.072052365 -2.59236 0.00259949 
Mxd4 0.357082667 0.037625397 0.834653 0.061427724 -2.33742 0.00268545 
Pim2 2.65015 0.553959475 8.942656667 0.785961471 -3.37439 0.00281836 
Rhbdf1 0.474124333 0.079911436 1.010115667 0.017970167 -2.13049 0.00281864 
Nbeal2 0.687516667 0.096001534 1.630303333 0.108596151 -2.37129 0.00288283 
Hbb-b2 5.538876667 1.178297203 16.2985 1.166132502 -2.94257 0.00290593 
Hbb-bt 5.538876667 1.178297203 16.2985 1.166132502 -2.94257 0.00290593 
Trim16 0.755176 0.085458859 3.33709 0.39034347 -4.41896 0.0029545 
Nlrp1b 0.049862033 0.014172652 0.864582333 0.125531692 -17.3395 0.00297538 
Mocs1 0.662081667 0.143404431 1.58091 0.016048459 -2.38779 0.00311914 
Mcf2l 0.098545233 0.009287629 0.339370667 0.036730921 -3.4438 0.00313933 
Pkdcc 0.010210333 0.010210333 0.133126333 0.016556651 -13.0384 0.00320866 
Ikzf4 0.565255 0.14273054 1.559456667 0.078559723 -2.75886 0.00364896 
Tgfbr3l 0.138265 0.045926213 0.43939 0.02149092 -3.17789 0.0040314 
6030498E09Ri
k 
1.360526667 0.137003315 2.886293333 0.220266452 -2.12145 0.00417531 
Trpv4 0.0181748 0.009150895 0.0848782 0.006715596 -4.67011 0.00418925 
Slc1a4 0.042971733 0.012014977 0.172579333 0.018545535 -4.01611 0.00421887 
Stk38l 3.255873333 0.311206795 6.84161 0.526479702 -2.10131 0.00422464 
Emp1 0.037814333 0.005305434 0.327030667 0.049171222 -8.64832 0.00426487 
Arid5a 1.021930667 0.175413149 2.059873333 0.028027209 -2.01567 0.00427767 
Cant1 0.905351667 0.172641374 3.217416667 0.362091346 -3.55378 0.0044963 
Ccdc166 0.711257 0.160436103 1.732353333 0.080009001 -2.43563 0.00469494 
6820408C15Ri
k 
0.033142533 0.009254596 0.091078067 0.004365584 -2.74807 0.0047972 
Slc5a2 0.1258928 0.051968334 0.666279333 0.080374086 -5.29244 0.00484634 
Mvp 1.421673333 0.118546831 3.068113333 0.26667964 -2.1581 0.00486012 
Nfkbib 1.218919 0.296693813 2.9821 0.103575351 -2.44652 0.0049577 
Rrad 0.183365667 0.053356841 0.536055333 0.033353894 -2.92342 0.00497597 
Chmp4c 0.0052634 0.0052634 0.036441533 0.001854269 -6.92357 0.00503431 
Il20rb 0.011406167 0.011406167 0.0799855 0.004554813 -7.01249 0.00504496 
Actn3 0.0728614 0.016187069 0.170465333 0.006676637 -2.33958 0.00507632 
Arhgef10 0.552997667 0.083410374 1.114276667 0.057195045 -2.01497 0.00515766 
Catsperg1 0.422413 0.047630803 1.093260667 0.111362387 -2.58813 0.00519503 
Slc27a1 0.947949333 0.188319793 2.09026 0.084390205 -2.20504 0.00520597 
Apobr 0.693869333 0.076745391 1.8039 0.185722923 -2.59977 0.00524586 
Robo3 0.095301133 0.008877602 0.229466333 0.022658373 -2.4078 0.00528224 
Ppargc1a 0.209158 0.023517331 0.445263333 0.035844287 -2.12884 0.00530227 
Usp35 0.0202492 0.000716668 0.0490892 0.005208703 -2.42426 0.00538019 
Ankrd50 0.369393333 0.073209077 0.840809667 0.048091908 -2.27619 0.00576111 
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N4bp3 0.066343367 0.007456307 0.200478 0.023788698 -3.02182 0.00576663 
Alkbh2 0.200382 0.053778366 0.747902667 0.086599215 -3.73239 0.00580316 
5031439G07Ri
k 
0.162060667 0.025245528 0.399275 0.036253512 -2.46374 0.00580901 
Cyp27a1 0.336269 0.092339351 1.094991333 0.106969858 -3.25629 0.0058107 
Vmn2r46 0.001179646 0.001167893 0.037470533 0.006681338 -31.7643 0.00588343 
Zc3h7b 0.906199667 0.239020758 2.46754 0.169126339 -2.72295 0.0059559 
Jak3 0.563116333 0.156881321 1.684543333 0.14045703 -2.99146 0.00598271 
Wls 14.14873333 1.740599064 28.51776667 2.06453346 -2.01557 0.00600073 
Antxr2 0.913632667 0.127777821 1.941916667 0.144990233 -2.12549 0.00600268 
Myo1e 0.0977176 0.03732688 0.376650667 0.036907759 -3.85448 0.00603089 
2810429I04Rik 0.125197567 0.027952431 0.436077 0.052215645 -3.48311 0.0063016 
Rnase4 1.614783333 0.206264847 3.405373333 0.274317219 -2.10887 0.00644004 
Rabac1 10.96643667 1.92361175 22.0298 0.906817211 -2.00884 0.00650611 
Ndrg4 0.303899 0.075807474 0.760378667 0.044624879 -2.50208 0.00656447 
Plekhg6 0.265297333 0.040595302 0.881090333 0.111927558 -3.32114 0.00664249 
Pcdhgb4 0.079867567 0.027666208 0.298491667 0.031992117 -3.73734 0.00665679 
Ubl3 4.386566667 0.510696227 9.480423333 0.84457002 -2.16123 0.00669278 
A430057M04Ri
k 
0.093523267 0.028114778 0.240201 0.005332572 -2.56836 0.00685872 
Akt1s1 0.361164667 0.015076045 1.20097 0.163357952 -3.32527 0.00689033 
Pacsin1 0.004508167 0.004508167 0.0743657 0.0128942 -16.4958 0.00691405 
Cbx8 0.312065333 0.035369103 0.737297 0.075294101 -2.36264 0.00692585 
Ppp1r15a 4.98721 0.731368959 12.24926667 1.218111914 -2.45614 0.00692838 
Foxp2 0.019791773 0.006692659 0.0544127 0.001221119 -2.74926 0.00703655 
Fos 0.998012667 0.449878858 13.54475333 2.439594991 -13.5717 0.00719231 
Ntng2 0.004896833 0.004896833 0.0651039 0.010916468 -13.2951 0.00732233 
Ropn1l 0.966026667 0.189067429 2.148866667 0.139770729 -2.22444 0.00732941 
Tmem86a 0.793568667 0.122674703 1.66543 0.123139946 -2.09866 0.00740665 
Hmga1 2.84386 0.438173195 7.58733 0.841833806 -2.66797 0.00750009 
BC018473 1.0232503 0.968333358 19.7004 3.611083231 -19.2528 0.00751338 
Yipf3 2.083826667 0.356103562 4.574633333 0.349745054 -2.1953 0.00754216 
Arrdc2 0.213781333 0.041029805 0.516808 0.044978748 -2.41746 0.00761166 
Pitpnm1 0.558114333 0.037578491 1.466636667 0.178631974 -2.62784 0.0076129 
Prx 0.0633828 0.024739957 0.251257667 0.028524072 -3.96413 0.0076205 
Tgm5 0.374542 0.077861079 1.208299 0.149142949 -3.22607 0.00772996 
Col4a6 0.002996367 0.001780941 0.026955533 0.004497682 -8.99608 0.0077455 
Ubxn6 2.949456667 0.511551808 6.247926667 0.426534426 -2.11833 0.00774847 
Gm17745 0.947168667 0.203242694 2.40827 0.214417192 -2.5426 0.00778569 
Osgep 3.904063333 1.278637655 10.30631667 0.209003928 -2.63989 0.00780834 
Ifi44l 0.017945 0.009414705 4.772526667 0.963153965 -265.953 0.00783779 
Tgfbi 2.02981 0.336256939 6.392096667 0.817431143 -3.14911 0.00784293 





0.004112967 0.004112967 0.080779167 0.015013034 -19.6401 0.00790002 
9130008F23Ri
k 
1.121753 0.162573918 2.38359 0.199711615 -2.12488 0.00804393 
Creld1 0.782961667 0.094293812 2.090046667 0.250050259 -2.66941 0.00809565 
Mzb1 0.1122292 0.035495147 0.559807 0.084570164 -4.98806 0.00816076 
Slc39a3 0.232284667 0.022732411 0.578308667 0.067244249 -2.48966 0.00819142 
Sbk2 0.0164988 0.0164988 0.132955667 0.017281959 -8.0585 0.0081953 
Klrb1a 0.085552167 0.05172135 0.527375333 0.074627015 -6.16437 0.00824345 
Slc25a47 0.047068467 0.00571749 0.22254 0.035641866 -4.728 0.00827302 
Nr4a3 0.004701723 0.002357394 0.0196899 0.002008122 -4.18781 0.00840024 
Pdpn 0.0086663 0.00458897 0.090673667 0.01636795 -10.4628 0.00849686 
Dgkh 0.068762967 0.023703525 0.182805 0.000953099 -2.65847 0.00860241 
Gm10406 0.006392667 0.006392667 0.070369167 0.011694935 -11.0078 0.00864736 
Pcsk4 0.339648 0.095481826 0.917828333 0.074073622 -2.7023 0.00874698 
Abca7 0.545889 0.112779963 1.111163333 0.035257242 -2.03551 0.00875068 
Pycr2 2.435936667 0.616663753 5.542826667 0.20850831 -2.27544 0.008822 
Serpinh1 0.873454333 0.052430028 2.65019 0.371085355 -3.03415 0.00903167 
Rassf9 0.0108958 0.005716399 0.054320933 0.007190694 -4.9855 0.00912226 
Igfbp4 3.536453333 1.099664446 9.3403 0.550907729 -2.64115 0.00917984 
Ncdn 0.398379 0.073223991 0.840782333 0.058952953 -2.11051 0.00926642 
Srcin1 0.001798723 0.001798723 0.0130836 0.001589681 -7.27382 0.00930141 
Mfsd10 5.717826667 1.56625718 13.17803333 0.265269481 -2.30473 0.00933462 
Eif4ebp1 6.357166667 1.531559341 14.71203333 0.906028716 -2.31424 0.00934204 
Tnfrsf1a 6.886783333 1.666057084 14.97343333 0.448813567 -2.17423 0.00940073 
Csnk1g2 1.014471667 0.147006306 2.30765 0.233922041 -2.27473 0.00944292 
Shd 0.0471436 0.016857478 0.130994333 0.006230329 -2.77863 0.00954913 
Tspan2 0.425516667 0.031111323 0.946856667 0.107375009 -2.2252 0.00956468 
Dusp5 0.1078194 0.018577238 0.3716 0.053435971 -3.44651 0.00957051 
Pgam2 0.088998033 0.003149832 0.219365333 0.027830347 -2.46483 0.00962812 
Rap1gap 0.253696 0.018833079 0.543847 0.059612924 -2.14369 0.00972559 
9030617O03Ri
k 
0.517218 0.004875179 1.164144 0.139378382 -2.25078 0.00974349 
Isyna1 2.943493333 0.930815693 7.415856667 0.258786925 -2.51941 0.0098131 
Dctn1 0.777758667 0.151527782 1.757436667 0.148035362 -2.25962 0.00984636 
S1pr4 2.007036667 0.326992213 5.310466667 0.636248372 -2.64593 0.00989686 
Ap2a1 0.242731 0.072777662 0.580578667 0.009144129 -2.39186 0.00998577 
Cfap45 0.059092833 0.032431439 0.249662333 0.025804434 -4.22491 0.0100449 
Fam195a 0.987151 0.324784114 2.839 0.238804753 -2.87595 0.0100787 
Fhod1 0.394418333 0.05089738 0.93464 0.106757909 -2.36966 0.0102786 
Spr 1.590534667 0.395378939 5.60443 0.786034439 -3.52361 0.0103239 
Habp2 0.0609394 0.012888552 0.126254333 0.006294131 -2.07181 0.0103885 
Rapgefl1 0.139962733 0.038459344 1.028098667 0.191568895 -7.3455 0.0104539 
Acvr1 0.460579333 0.106095883 0.952711 0.023005565 -2.06851 0.0105515 
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Rps6kb2 2.218486667 0.449017601 4.65213 0.295379783 -2.09698 0.0105933 
Syne4 0.125009467 0.032588244 0.382222 0.046597719 -3.05755 0.0106304 
Fam110a 4.396153333 1.023276815 9.053606667 0.119229342 -2.05944 0.0106508 
Anapc7 1.555515667 0.375203716 3.34815 0.133230202 -2.15244 0.0108031 
Prpf19 0.602152 0.16424439 1.60163 0.150125422 -2.65984 0.0108918 
Ormdl3 5.17696 1.278010113 12.57833333 1.053104547 -2.42968 0.0110792 
Ccdc86 0.846981 0.171764671 1.826206667 0.13663777 -2.15613 0.0111476 
Arhgef10l 0.02576895 0.009591266 0.1180457 0.018366145 -4.58093 0.0112159 
Ildr2 0.00355222 0.000777728 0.010093223 0.001246157 -2.84139 0.0112217 
Josd2 2.029453333 0.570284623 5.23539 0.439790997 -2.5797 0.0112324 
Nkx6-2 0.124179933 0.032731669 0.301258667 0.022737716 -2.42598 0.0113064 
Acap1 13.60256667 2.51412225 29.9975 2.701754436 -2.20528 0.0113131 
Gipc1 1.039609667 0.332525714 2.723076667 0.182040184 -2.61933 0.0113271 
Speg 0.148107133 0.060595155 0.424767333 0.014580328 -2.86797 0.0113427 
Ccdc64 0.0897459 0.042603406 0.436274 0.065518057 -4.86121 0.0113863 
Syt14 0.0193461 0.004502389 0.060783533 0.008214162 -3.1419 0.011478 
2010107G23Ri
k 
0.188031667 0.061051341 0.501440333 0.036008077 -2.66679 0.0114954 
5031434O11Ri
k 
0.511774667 0.067698494 1.169991 0.132632639 -2.28614 0.0115092 
Mink1 0.796622 0.085586539 1.896483333 0.234283637 -2.38066 0.0116046 
Nox4 0.034155693 0.030474845 0.234500333 0.033826724 -6.86563 0.0116886 
Arhgef40 0.561027667 0.064402341 1.327976667 0.162018363 -2.36704 0.0117005 
Matk 4.612493333 1.193901391 10.29729667 0.494763049 -2.23248 0.0117023 
Chchd2 15.03397 4.998046001 38.0728 1.59850214 -2.53245 0.0117783 
Rab1b 3.992196667 0.955393056 8.526783333 0.396285311 -2.13586 0.0118367 
Nectin1 0.118975367 0.01497338 0.270812333 0.031231418 -2.27621 0.0118392 
Nectin2 0.082754633 0.025935308 0.263571 0.032081829 -3.18498 0.011847 
Nr1d2 1.014303 0.235823559 2.068486667 0.050685174 -2.03932 0.0119643 
Adora1 0.005713923 0.003572003 0.0359262 0.005928878 -6.28747 0.0120166 
Slc15a3 0.058447567 0.013078842 0.196172 0.028742982 -3.35638 0.01205 
Sart3 0.727451667 0.056576713 1.528033333 0.174809519 -2.10053 0.0120884 
Lgi3 0.004931007 0.002611061 0.046918067 0.009282934 -9.51491 0.0121182 
Lonrf2 0.008636667 0.008636667 0.054257733 0.005949057 -6.28225 0.0121559 
Ltbp4 0.0497649 0.022940353 0.366372667 0.069449548 -7.36207 0.0123617 
Als2cl 0.759714 0.020132116 1.531596667 0.177261906 -2.01602 0.0123822 
Gnai1 0.0977782 0.015651688 0.234481667 0.027518269 -2.3981 0.0124656 
Pdgfra 0.007647233 0.007647233 0.0472041 0.005046373 -6.1727 0.0124731 
Homer1 0.265617667 0.064524615 0.656434 0.063634906 -2.47135 0.0125216 
Gm20605 0.1334674 0.066935795 0.617791 0.090549156 -4.62877 0.0126342 
Cxcr3 0.1639044 0.054351041 0.609519 0.088214007 -3.71874 0.0126383 
Lama4 0.038935967 0.009343824 0.132484667 0.019655656 -3.40262 0.0126614 
Ctbp1 3.633906667 0.850050357 7.61633 0.370560204 -2.09591 0.0126997 
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Tnfsf12 0.555146667 0.110261574 1.113966333 0.069788457 -2.00661 0.012823 
Dmrtc1a 0.011771867 0.011771867 0.066270833 0.004872074 -5.6296 0.0128711 
Lin28b 0.050335967 0.017851445 0.13721 0.009754187 -2.72588 0.0129443 
Abr 0.844857667 0.192669734 2.262706667 0.271009847 -2.6782 0.0130123 
Iba57 0.1291109 0.047818378 0.336961 0.009735063 -2.60986 0.0130609 
Chpf2 0.416868 0.187363722 1.370263333 0.12273075 -3.28704 0.0130893 
Cc2d1a 0.602065 0.148004272 1.249926667 0.037203851 -2.07606 0.0132081 
Ninj1 13.69235333 3.575939849 29.42513333 0.97420154 -2.14902 0.0132117 
Llgl2 0.0618692 0.007124818 0.125014333 0.013063636 -2.02063 0.0132254 
Ooep 0.063253567 0.023166631 0.177426667 0.013694122 -2.805 0.0132366 
Plpp7 0.297023 0.114221837 0.832968667 0.055204716 -2.80439 0.0134279 
Zfp36 8.31855 2.573426921 38.933 6.800684618 -4.68026 0.0135827 
Ddx54 0.490287 0.151296703 1.129616667 0.016572014 -2.304 0.0136897 
Rps10 73.6621 14.4877046 149.5 10.82877585 -2.02954 0.0137747 
Rbck1 2.28045 0.569053983 4.734306667 0.13755778 -2.07604 0.0137903 
Sema7a 0.063891657 0.032300704 0.209551333 0.01285341 -3.27978 0.0138074 
Actr1b 4.308726667 0.649417421 8.814836667 0.864505493 -2.04581 0.0140601 
4930404N11Ri
k 
0.411395667 0.086155608 1.057733667 0.129176538 -2.57109 0.0141152 
9330151L19Ri
k 
0.35659 0.033613451 0.724621 0.081795594 -2.03208 0.0141257 
Cltb 1.693653333 0.291028488 3.799183333 0.414696299 -2.24319 0.0141914 
Ddah2 5.069463333 0.819683192 11.39647667 1.284108259 -2.24806 0.0142238 
Sars2 0.848881333 0.093459817 1.765893333 0.200286361 -2.08026 0.0142717 
Plekhf1 0.477408 0.078055913 1.097690333 0.127553119 -2.29927 0.0142847 
Klrb1b 0.0058385 0.0058385 0.102910067 0.022697562 -17.6261 0.0143541 
Med25 0.401475 0.092037224 0.809879667 0.035491365 -2.01726 0.014374 
Osbpl5 0.447100333 0.04213013 1.063348 0.143054495 -2.37832 0.0144672 
Ephb4 0.314247 0.074951667 0.902001333 0.121386382 -2.87035 0.0146133 
Ydjc 0.250072333 0.061219053 0.549812667 0.039378177 -2.19862 0.0146377 
Ctsf 3.070153333 0.704543228 6.534886667 0.460980932 -2.12852 0.0146707 
Ldb1 2.753656667 0.51192006 6.129093333 0.641409077 -2.2258 0.0146946 
Hyls1 0.468588 0.133158977 1.051751667 0.048854824 -2.24452 0.0147145 
Hist1h2bc 3.226696667 0.401391881 8.764876667 1.286692971 -2.71637 0.0147455 
Sh3rf3 0.01286424 0.001562644 0.028842767 0.003561087 -2.24209 0.0147464 
Swsap1 0.607752667 0.073331051 1.250773333 0.13870691 -2.05803 0.0148734 
Tpd52l1 0.1919089 0.069094164 0.602528 0.0726624 -3.13966 0.0149117 
Kazn 0.289347333 0.070564683 0.816500667 0.107778704 -2.82188 0.0149503 
Dagla 0.00222366 0.00222366 0.019840267 0.003689852 -8.92235 0.0149852 
Gchfr 4.31352 0.611510177 10.14852667 1.290594205 -2.35272 0.0150276 
Mrpl38 1.432590333 0.334249014 3.721833333 0.45038817 -2.59797 0.0150783 
Cox5b 18.81763333 4.604065158 40.8317 2.820884703 -2.16986 0.0151352 
Ercc2 0.347670333 0.023848501 1.235740333 0.21684086 -3.55435 0.0152112 
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Ube2e2 1.162501333 0.158855993 2.61364 0.319136467 -2.24829 0.0152147 
Pla2g1b 0.022695833 0.022695833 0.118171 0.006013084 -5.20672 0.0152677 
Cystm1 0.042196667 0.027934713 0.171147333 0.015015725 -4.05595 0.0152734 
Ctu2 0.543544 0.143063885 1.54188 0.199692935 -2.83672 0.0152975 
5730559C18Ri
k 
0.002079007 0.002079007 0.0224837 0.004597919 -10.8146 0.015557 
Pik3r6 0.031319 0.016327018 0.530735667 0.122482414 -16.9461 0.015582 
1700052K11Ri
k 
0.117972633 0.01686239 0.237416 0.024272513 -2.01247 0.015586 
Dusp1 1.266375 0.283255003 6.15678 1.177071749 -4.86174 0.0156116 
Fndc7 0.006415333 0.006415333 0.034108767 0.002425005 -5.31677 0.0156308 
Arhgap27 1.066471 0.219586741 2.301116667 0.213739821 -2.15769 0.0157464 
Hmga1-rs1 6.7367 2.278042051 19.25726667 2.114722373 -2.85856 0.0157584 
Ap2s1 5.335403333 1.130528859 11.73806333 1.120873197 -2.20003 0.015841 
Piezo1 0.1731288 0.066846906 0.558983 0.068933388 -3.22871 0.0158857 
Apba3 0.234391333 0.072229523 0.578672667 0.046153684 -2.46883 0.0159102 
Zfp213 0.258436667 0.023786722 0.901392667 0.158318844 -3.48787 0.0159164 
Gramd1a 1.874383333 0.199546038 3.949203333 0.477069015 -2.10694 0.0159664 
Hsd17b14 0.183401567 0.077580235 0.632191 0.080747759 -3.44703 0.0160249 
Slc6a9 0.1144772 0.03191112 0.37069 0.055427267 -3.23811 0.0160496 
LOC10524650
6 
0.311938667 0.070027076 0.705764 0.069101172 -2.26251 0.0160888 
Akna 0.57413 0.100486602 1.203431333 0.121143674 -2.09609 0.0161541 
Map3k6 0.025328367 0.013039165 0.100462833 0.013539384 -3.96642 0.0161692 
Ppp1r37 0.1405475 0.032039739 0.384254333 0.051897108 -2.73398 0.0161865 
Gramd4 0.732592 0.07526533 2.25635 0.373912268 -3.07995 0.0161969 
Igsf9 0.0468321 0.009746211 0.116214233 0.014399751 -2.48151 0.0162618 
Gm5129 0.098729367 0.076499012 0.461355333 0.049219797 -4.67292 0.0163136 
Slco3a1 1.43077 0.221002678 2.90937 0.298630612 -2.03343 0.0164019 
Bmp8a 0.0890998 0.010262219 0.338454 0.062089424 -3.7986 0.0166454 
Fam219a 0.047198867 0.024019524 0.157688333 0.014338698 -3.34094 0.0168214 
Csf2rb2 1.021685 0.17516212 2.051296667 0.193194766 -2.00776 0.0168432 
Rcl1 3.700123333 0.907099763 8.011343333 0.610394738 -2.16516 0.0169154 
Rilpl2 2.389436667 0.390552902 5.318046667 0.632149299 -2.22565 0.016942 
Tmem17 0.287236333 0.040136539 0.644322667 0.081316618 -2.24318 0.0169917 
Ppcs 2.208613333 0.53593801 4.773956667 0.370630512 -2.16151 0.0170038 
Zfp85os 0.154240633 0.036920404 0.328996667 0.024693994 -2.13301 0.0170398 
Axl 1.163254 0.213338257 2.53546 0.276161715 -2.17963 0.0170715 
Edn3 0.012419633 0.006970997 0.042557167 0.003231834 -3.42661 0.0172148 
2410004P03Ri
k 
0.1809276 0.106237791 0.632336333 0.044456505 -3.49497 0.0172523 
Itga3 0.1195369 0.039596625 0.297697 0.022419398 -2.49042 0.0173154 
Ptprf 0.025868857 0.011429918 0.089794733 0.011659665 -3.47115 0.0173176 
Cnn3 0.290046 0.024146411 0.899349 0.153772578 -3.10071 0.0173293 
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Palm 0.100978433 0.018567257 0.323998 0.053923842 -3.20859 0.0173863 
Hist1h1c 1.030044 0.413932684 2.874066667 0.227833175 -2.79024 0.0175003 
C2cd2l 0.149037967 0.030530735 0.406286667 0.058543278 -2.72606 0.0175986 
Sbf1 0.671631667 0.13089694 1.787343333 0.255564435 -2.6612 0.0177561 
Zfp618 0.200050667 0.013102435 0.453612333 0.063952771 -2.26749 0.0177785 
Prodh 3.829136667 0.764066647 8.52968 0.939204051 -2.22757 0.0178053 
Tox3 0.0039236 0.0039236 0.076584967 0.018312966 -19.519 0.0178458 
Spsb4 0.062417033 0.006626427 0.165065667 0.02563388 -2.64456 0.0178872 
Plxna3 0.383510667 0.04650308 0.774 0.089383048 -2.0182 0.0179084 
Fzd2 0.00259688 0.00259688 0.0301777 0.00664189 -11.6207 0.0180324 
Ier3 5.315423333 1.264931403 11.22464667 0.860324813 -2.11171 0.018104 
Hbegf 0.562839333 0.089602627 1.160595 0.126195596 -2.06204 0.018113 
AI467606 6.251883333 1.323362059 12.59283333 0.971934842 -2.01425 0.0181185 
Csrnp1 1.75316 0.351353125 3.540573333 0.302052914 -2.01954 0.0181833 
Ptpn18 5.891523333 1.410828681 11.90686667 0.667460751 -2.02102 0.018238 
Vars 1.57608 0.598130464 4.63813 0.526599213 -2.94283 0.0184218 
Gli1 0.033760033 0.00569679 0.097891633 0.015700947 -2.89963 0.0184652 
Tjap1 0.753126333 0.237541024 1.70026 0.068273935 -2.25761 0.0185842 
Cdh15 0.173166667 0.018395188 0.558383667 0.098845385 -3.22455 0.0185961 
Nrbp2 0.243588667 0.083556236 0.751075667 0.102884811 -3.08337 0.0186353 
Tmcc3 0.107290667 0.011540489 0.219394333 0.026955493 -2.04486 0.0187269 
Rn45s 40.1307 9.8452222 83.4362 5.603334637 -2.07911 0.0187327 
Sdsl 2.28522 0.472119522 4.63699 0.394423322 -2.02912 0.0187333 
Cox4i2 2.26057 0.337300506 7.883236667 1.438012321 -3.48727 0.0189934 
Zc3h12a 0.0577953 0.019008379 0.146227333 0.01339867 -2.53009 0.0190615 
Shb 0.0919995 0.011765513 0.341726333 0.064620273 -3.71445 0.0190705 
Hopx 0.005080333 0.005080333 0.042597667 0.008474774 -8.38482 0.0191536 
Sv2a 0.0668411 0.003271014 0.232057667 0.043401844 -3.47178 0.0191714 
Gfod2 0.806866 0.196664526 1.89332 0.208552592 -2.34651 0.019267 
5430416N02Ri
k 
4.084133333 0.581628571 8.232483333 0.931339927 -2.01573 0.0194705 
Ccdc107 3.963153333 1.472821389 9.531103333 0.101522237 -2.40493 0.0195788 
Fuz 0.710834 0.15096398 1.42789 0.115656342 -2.00876 0.0195954 
Cmtm8 0.797993667 0.126874827 1.82888 0.242184737 -2.29184 0.0195956 
AI661453 0.0376995 0.010181231 0.095002 0.011295172 -2.51998 0.0196337 
Il17re 0.704684333 0.240602032 2.59543 0.440775773 -3.68311 0.0196869 
Atp5d 14.11860667 5.115053191 33.96246667 1.418600538 -2.40551 0.0201494 
Coro1a 43.42803333 8.914485352 90.4071 8.914651076 -2.08177 0.0203606 
Tmbim7 0.033284367 0.009685259 0.082810667 0.009192607 -2.48798 0.0206731 
Fbxw4 0.979474333 0.056144875 1.976056667 0.263499197 -2.01746 0.0208531 
Dennd2a 0.207481667 0.023751721 0.568415 0.094871179 -2.73959 0.0210084 
Dhrs11 1.754946667 0.297874627 3.88785 0.496433782 -2.21537 0.0211271 
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Kdf1 0.040131233 0.012484761 0.1273811 0.020124723 -3.17411 0.0211277 
Slc3a2 4.63746 0.500011096 9.444576667 1.207895353 -2.03659 0.0212576 
Kctd13 0.419219 0.102993781 0.990992 0.116971003 -2.36389 0.0214159 
Gbp2b 0.081084467 0.026977639 2.736186667 0.723770812 -33.7449 0.0214689 
Arrb2 1.030261667 0.233971065 2.134973333 0.192332012 -2.07227 0.0218209 
Il3ra 0.136733333 0.007837811 0.375769 0.065217778 -2.7482 0.0219837 
Actr1a 6.837883333 1.174951453 16.89003333 2.504799956 -2.47007 0.0220952 
Klhl11 0.0764445 0.033699651 0.198973333 0.001274449 -2.60284 0.0220952 
Tnfrsf13c 1.647383333 0.357019108 4.123266667 0.581446473 -2.50292 0.0221856 
St3gal2 1.096093667 0.184814475 2.305953333 0.278788237 -2.10379 0.0224148 
St6galnac2 0.202008567 0.114233073 2.562063333 0.642887359 -12.6829 0.0224684 
Adam11 0.425179667 0.054319989 1.72806 0.356425964 -4.06431 0.0224832 
Cog8 0.1560078 0.074634291 0.475682333 0.047897192 -3.0491 0.0226622 
S100a2 0.019885867 0.019885867 0.116198733 0.01787371 -5.84328 0.0227155 
Prex1 0.664112333 0.128983235 1.500613333 0.193156914 -2.25958 0.022727 
Trim46 0.439176333 0.069092271 0.972915 0.131226717 -2.21532 0.0227795 
Tmcc2 0.482471 0.10709657 1.006408 0.098717372 -2.08594 0.0228157 
Nr1d1 1.028071667 0.094535753 2.111276667 0.286201224 -2.05363 0.0228838 
Enkur 0.91934 0.190048296 2.32171 0.341725138 -2.5254 0.0230344 
Med16 0.571185333 0.075288669 1.233495667 0.168796939 -2.15954 0.0230966 
Jag2 0.083637467 0.0132743 0.210892667 0.032958553 -2.52151 0.0231364 
Sfxn2 2.866673333 0.123921828 5.935563333 0.848211787 -2.07054 0.0231662 
Mpst 0.139135533 0.050030989 1.339588667 0.332378336 -9.62794 0.0233451 
Nle1 3.55372 0.458710427 7.897536667 1.126569626 -2.22233 0.023353 
Smg9 0.687807333 0.177054107 1.48776 0.137633939 -2.16304 0.0234363 
Arhgef17 0.084385367 0.028409672 0.239278 0.032917874 -2.83554 0.0235394 
Cd248 0.1051939 0.062649776 0.332402333 0.012126583 -3.1599 0.0235743 
Mfsd4b4 0.0942904 0.061743172 0.323737333 0.018473403 -3.4334 0.0235818 
Fam131a 0.285012 0.020465809 0.913094 0.175867324 -3.2037 0.0238538 
Vps4a 2.750623333 0.481561955 5.58385 0.638548622 -2.03003 0.0239592 
Xrcc1 1.346107667 0.350911878 2.87349 0.250797236 -2.13467 0.023988 
Ear12 0.001324285 0.001324273 0.1078603 0.030093417 -81.448 0.0240835 
Ear3 0.001324285 0.001324273 0.1078603 0.030093417 -81.448 0.0240835 
Fasn 0.670196667 0.174727275 1.39532 0.108015458 -2.08196 0.0242317 
Rcor2 0.250365667 0.071005708 0.616969 0.076204847 -2.46427 0.0244574 
Guk1 6.10286 1.485784062 13.67083333 1.560774231 -2.24007 0.0246276 
Dmap1 1.979743333 0.538199332 4.05105 0.243882667 -2.04625 0.0247732 
Dlk1 0.047821467 0.00435456 0.104988833 0.015748963 -2.19543 0.024927 
Arhgap20os 0.040877033 0.01772408 0.1190613 0.013655451 -2.91267 0.0250237 
Skint3 0.458962333 0.054118335 0.933059667 0.124425712 -2.03298 0.0250297 
Syt3 0.075596867 0.024391517 0.190738667 0.022295328 -2.5231 0.0252535 
86 
 
Sox13 0.252573667 0.078908714 0.54087 0.024921174 -2.14143 0.0252618 
Lrrc61 0.401493667 0.098663381 1.036286333 0.153981906 -2.58107 0.0255581 
Gna15 1.478567333 0.461951312 3.590053333 0.39612847 -2.42807 0.0255886 
Fkbp10 0.384346667 0.12160053 1.029982333 0.14163932 -2.67983 0.0258515 
Sbno2 1.455126333 0.445219169 3.71239 0.478031203 -2.55125 0.0259253 
Shf 0.024156033 0.01207805 0.090120633 0.014846402 -3.73077 0.0261346 
Mier2 0.342641 0.15465346 1.037982667 0.129610572 -3.02936 0.0261505 
Bzrap1 0.013765403 0.004817022 0.0424097 0.006775537 -3.08089 0.0261598 
Pigt 0.918496667 0.283048844 2.198133333 0.242179594 -2.39319 0.0264111 
Scarf1 5.40991 1.142927495 12.20925667 1.617221846 -2.25683 0.026452 
Slc7a3 0.0114649 0.005748377 0.105203367 0.026776994 -9.17614 0.0267133 
Ptgfrn 0.002710947 0.001435496 0.0411714 0.01116713 -15.1871 0.0268797 
Depdc1b 0.587025333 0.112159014 1.531686667 0.253481974 -2.60924 0.0270766 
Sntb1 0.00290945 0.00290945 0.043845233 0.011657232 -15.0699 0.0270993 
Slc9a1 0.976814 0.11423339 2.386446667 0.398051208 -2.44309 0.027179 
Skap1 0.191146 0.030591446 0.480052667 0.079277117 -2.51144 0.0272796 
Rab4a 2.933636667 0.632164015 6.337033333 0.77642828 -2.16013 0.0272977 
Plod3 0.801357667 0.204448293 1.66378 0.150292969 -2.0762 0.0273086 
Retn 0.010762967 0.010762967 0.1271686 0.032550853 -11.8154 0.0273951 
1110004E09Ri
k 
2.390666667 0.719571439 4.92496 0.212645414 -2.06008 0.0278485 
Ap1m2 0.090029867 0.034365042 0.224465 0.020085667 -2.49322 0.0278529 
Rbfa 0.539155667 0.131652165 1.186113667 0.139651358 -2.19995 0.0280202 
4430402I18Rik 0.223297 0.028971028 0.566979667 0.097776409 -2.53913 0.0280397 
Sertad1 2.287246667 0.843580904 6.359443333 0.868877572 -2.78039 0.0282366 
Dctn2 4.866363333 0.804290098 10.10233333 1.333807325 -2.07595 0.0282608 
Zfp777 0.236993667 0.088775965 0.596568 0.060054599 -2.51723 0.0284409 
Clcn2 0.188677 0.019093275 0.501410333 0.091309365 -2.65751 0.0285032 
Ifi204 0.898118333 0.705646258 4.464303333 0.797146693 -4.97073 0.0285746 
S1pr3 0.217457667 0.058648291 0.481747333 0.052987733 -2.21536 0.0287355 
Thy1 0.208380333 0.083443494 0.557137333 0.062592392 -2.67366 0.028743 
Gm12709 0.003276177 0.003276177 0.014972667 0.001238604 -4.57016 0.0288498 
Pnmal2 0.006054267 0.004008 0.037150267 0.008420147 -6.13622 0.0289823 
Tnfsf8 0.0295551 0.015215101 0.087687567 0.008542124 -2.96692 0.0290631 
Aoc2 0.179636333 0.007761101 1.573125 0.418352636 -8.75728 0.0290969 
Brinp2 0.006109767 0.006109767 0.0361564 0.0066598 -5.91779 0.0292541 
Padi4 2.51948 0.728622975 5.116 0.283810435 -2.03058 0.0293624 
Eng 2.07934 0.648322603 4.389993333 0.25641737 -2.11124 0.0295372 
Atp13a2 1.126154333 0.089893583 2.55249 0.421674429 -2.26655 0.0297039 
Carmil2 0.283287 0.075244774 0.587751667 0.053210485 -2.07476 0.0298292 
Apof 0.069379467 0.019429192 0.139211333 0.00834186 -2.00653 0.0298581 
Crat 0.618759 0.145712529 1.23837 0.119489973 -2.00138 0.0302697 
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Agpat3 0.475228667 0.113266244 1.015573333 0.119289679 -2.13702 0.0303628 
Alox12 0.1194261 0.029542944 0.331985 0.057690451 -2.77984 0.0305159 
Lrp10 1.995173333 0.543736282 4.740686667 0.638647009 -2.37608 0.0306937 
Atp8b5 0.329571333 0.048822923 0.780222667 0.128938317 -2.36739 0.0308293 
Gm13032 0.643332333 0.085944678 1.323182 0.190051566 -2.05677 0.0310984 
Itpr3 0.264297667 0.0348777 0.540877333 0.077360205 -2.04647 0.0311019 
Rhobtb2 0.553912333 0.059497068 1.132385333 0.16723972 -2.04434 0.0311144 
Ptprcap 14.76837667 4.857788901 36.3038 4.484281223 -2.45821 0.0311557 
Tecpr1 0.572600667 0.07119735 1.151356 0.162887423 -2.01075 0.0312073 
Rarg 0.231730333 0.052810114 0.465601333 0.048707496 -2.00924 0.0312181 
Abcb10 0.943580333 0.157249997 2.192726667 0.350058229 -2.32383 0.0312266 
Trpm5 0.0498963 0.018853535 0.140926333 0.020743233 -2.82439 0.0314511 
Mrpl54 7.12604 3.080496351 17.52076667 0.894933518 -2.4587 0.0316622 
Gltscr2 7.856193333 1.419109917 16.37106667 2.213834476 -2.08385 0.0317325 
Pde1b 0.553770333 0.0855416 1.160881 0.166998502 -2.09632 0.0318047 
Abcc3 0.201875667 0.04390105 0.527297333 0.09098231 -2.61199 0.0322392 
Arhgap27os3 0.430301 0.066455843 1.785856667 0.416377394 -4.15025 0.0324373 
Gaa 6.59004 0.674459541 13.3889 2.00604893 -2.03169 0.0325117 
Tnfrsf25 0.236425 0.051111688 1.190326667 0.292823936 -5.03468 0.0326176 
Gas2l1 0.096061833 0.018299119 0.215584333 0.03248773 -2.24422 0.0327293 
Gpr165 0.031732167 0.025588274 0.115731667 0.005694155 -3.64715 0.0327643 
9430065F17Ri
k 
0.2022118 0.088787033 0.492177333 0.01758054 -2.43397 0.0327865 
Tmem160 0.250288333 0.072751497 0.726931 0.129975178 -2.90437 0.0329008 
Gtf2h4 3.14329 0.745500609 6.374566667 0.683568882 -2.02799 0.033068 
Tymp 0.132260667 0.029541251 0.333190667 0.055546462 -2.51919 0.0330974 
Tjp3 0.0457043 0.00503483 0.138543667 0.028666151 -3.03131 0.0332222 
Fads3 0.415832 0.082392948 0.962359 0.150349411 -2.3143 0.0332873 
Klhl32 0.0118869 0.0118869 0.10727 0.027501548 -9.02421 0.033419 
Dohh 0.438886667 0.183989342 1.171032667 0.138556982 -2.66819 0.0335758 
Jam3 3.2107 0.377817498 6.882506667 1.091608264 -2.14362 0.0335781 
Itprip 1.153834333 0.212467853 2.33146 0.303870532 -2.02062 0.0336616 
Pnpla2 6.97133 1.883993747 14.1243 1.241030737 -2.02606 0.0338374 
Ppp1r9b 2.350596667 0.475515034 4.79834 0.608566566 -2.04133 0.0338781 
Ryr2 0.004292133 0.002428115 0.012700733 0.001076564 -2.95907 0.0339943 
Gm16287 0.045008533 0.030142132 0.142719667 0.006706962 -3.17095 0.0340436 
Gtpbp6 0.461381 0.104286816 0.943702667 0.11133209 -2.04539 0.0341257 
Zfp995 0.073510867 0.024096244 0.176478 0.022020219 -2.40071 0.0343677 
Dzip1l 0.0188312 0.009433715 0.0976987 0.023215813 -5.18813 0.0346061 
Znhit2 0.1047139 0.048226088 0.368558333 0.068586992 -3.51967 0.0346196 
Acsbg1 0.0860138 0.013696781 0.230920667 0.043971289 -2.68469 0.0346348 
A230056J06Ri
k 
0.0650326 0.012181395 0.14672 0.022929018 -2.2561 0.0346413 
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Lrguk 0.00821028 0.005435306 0.060880333 0.015858503 -7.41514 0.034786 
Plekha7 0.157631767 0.062537056 0.360629 0.017178494 -2.28779 0.0351825 
Qprt 0.168718 0.041592955 0.574049 0.123300572 -3.40242 0.0357024 
BC037034 0.272138667 0.089265792 0.555513 0.017813032 -2.04129 0.0357635 
Agbl1 0.039492667 0.006114671 0.0974262 0.017586839 -2.46695 0.0358221 
1700067G17Ri
k 
0.0713055 0.032603647 0.562312333 0.154563652 -7.88598 0.03593 
Treml1 0.949284667 0.162500149 2.025353333 0.305756681 -2.13355 0.0359508 
E230013L22Ri
k 
0.124068267 0.018856351 0.282096 0.047373072 -2.27372 0.0362456 
Gem 1.834093333 0.212528901 3.879716667 0.625487795 -2.11533 0.0363418 
Dab1 0.007275307 0.004970059 0.0231325 0.001256571 -3.17959 0.0364605 
Gpr173 0.0191817 0.012153375 0.071685033 0.011908434 -3.73716 0.0367279 
Fam135a 0.159568333 0.028051701 0.382518667 0.066592425 -2.3972 0.0367383 
Tmem189 0.570634 0.055650484 1.283563333 0.224526358 -2.24937 0.0368593 
Ckb 0.488838667 0.207836028 1.13405 0.027703737 -2.31988 0.0370329 
Hexim2 0.216845 0.03462946 0.537898333 0.098490916 -2.48056 0.0371053 
Cntn3 0.001208577 0.001208577 0.014061763 0.004002472 -11.635 0.0371401 
Hist1h2bp 0.140177867 0.041311215 0.511851 0.114071056 -3.65144 0.0375284 
Smoc1 0.0711903 0.029242437 0.212768333 0.035786147 -2.98873 0.0375297 
Sesn2 0.325877 0.161124338 0.916585 0.107029572 -2.81267 0.0378868 
Lmnb2 0.824516 0.216573603 1.657753333 0.166176302 -2.01058 0.0379399 
Usf2 1.213154333 0.293035721 2.562323333 0.331067456 -2.11212 0.0379708 
Cxx1a 0.127989557 0.085989928 1.157968667 0.326890878 -9.04738 0.0381338 
Rasd1 0.7922 0.153753973 1.88145 0.322839258 -2.37497 0.0381719 
Agpat9 0.066330033 0.025610218 0.269707333 0.061796044 -4.06615 0.038389 
Gpr4 0.199165633 0.073759922 0.826804333 0.192826234 -4.15134 0.038398 
Akr1c14 0.041914167 0.026954384 0.272268 0.070854408 -6.49585 0.0384534 
Entpd3 0.197839333 0.037594718 0.425365 0.064796042 -2.15006 0.0385068 
Cpe 0.0289835 0.017613764 0.093045733 0.011609056 -3.2103 0.0385232 
Plekhg1 0.180521667 0.027145404 0.371080667 0.056653871 -2.0556 0.0386533 
Phc2 1.264682 0.342979999 3.111313333 0.503136964 -2.46016 0.0386799 
Klrb1c 0.957277 0.082700421 2.21068 0.405587746 -2.30934 0.0388563 
Tctn2 0.446286 0.151628727 1.061549333 0.135360775 -2.37864 0.0388947 
Clip2 0.194953667 0.017722886 0.423597667 0.073431583 -2.17281 0.0389029 
Ccdc103 0.033826233 0.028764504 0.164748667 0.032464098 -4.87044 0.039223 
1110008P14Ri
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0.288321333 0.056928502 0.943114 0.209349111 -3.27105 0.0392342 
Git1 0.987949 0.089308346 2.64485 0.542188798 -2.67711 0.0393438 
Ccdc120 0.152074 0.020152392 0.3075 0.04745593 -2.02204 0.0393718 
Gadd45g 0.664067333 0.099200479 2.362773333 0.554860789 -3.55803 0.0394063 
Agap3 0.452156333 0.070569855 1.188596333 0.234085138 -2.62873 0.0394676 
Jun 1.298306667 0.542993297 6.66715 1.697985213 -5.13527 0.0394863 
Camk2n1 0.038766833 0.028198376 0.126081 0.00687478 -3.25229 0.0396159 
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Boc 0.1087929 0.035322298 0.264007667 0.037690363 -2.4267 0.0397517 
Egr1 2.021918333 0.713394456 8.03635 1.873387801 -3.97463 0.0399313 
Rara 0.064549367 0.01911577 0.252864333 0.059791462 -3.91738 0.0399442 
Ccm2l 0.846652 0.13408799 1.985413333 0.355320469 -2.34502 0.0400017 
Bcar3 0.0291718 0.008488545 0.079035133 0.014311822 -2.7093 0.0400752 
Anks1 1.454817 0.324914244 3.09852 0.44222053 -2.12984 0.0401258 
Asic1 0.031068063 0.013186444 0.106170467 0.021346137 -3.41734 0.040209 
Ifi211 0.441594 0.194900402 1.35595 0.23527553 -3.07058 0.0402264 
Rnpepl1 0.710759333 0.16353501 1.754006667 0.308047766 -2.46779 0.0402882 
Ccdc116 0.062012633 0.024744778 0.196072333 0.037406286 -3.16181 0.0403755 
Rell2 0.545471333 0.131962172 1.383736667 0.247559234 -2.53677 0.0404146 
Smurf1 0.405169667 0.09134364 0.853577 0.11928753 -2.10672 0.0405571 
Ier2 1.914716667 0.319216165 4.903293333 0.951970586 -2.56084 0.040881 
Rtbdn 0.0049379 0.0049379 0.028690967 0.006314661 -5.81037 0.0414236 
P2ry10 0.562403333 0.172457083 1.139546667 0.091084282 -2.02621 0.0415881 
Rasgrp3 0.179773667 0.021276631 0.440880667 0.085680428 -2.45242 0.0416524 
Lrch2 0.239596667 0.046444661 0.535351333 0.088879284 -2.23439 0.0420023 
Cracr2b 0.467935667 0.030398763 1.056253667 0.197362256 -2.25726 0.0421294 
Scimp 0.205343333 0.096105666 1.004348 0.253690711 -4.89106 0.0421672 
Magee1 0.347435 0.091562547 0.710094 0.082707334 -2.04382 0.0424224 
Rapgef3 0.270549 0.023012612 0.690636333 0.141154302 -2.55272 0.0425029 
Uchl1 0.279291 0.080742855 0.696288 0.117216994 -2.49306 0.0428272 
Gm16675 0.129234467 0.049248545 0.444534333 0.095693345 -3.43975 0.0428274 
Pcdhgb6 0.271277 0.095833996 0.611251333 0.065638613 -2.25324 0.0429494 
Bmp1 0.825521 0.07068801 1.716603333 0.29623582 -2.07942 0.0429904 
Gnb2 2.475576667 0.476402989 4.964303333 0.7059599 -2.00531 0.0431495 
Ext2 1.336978667 0.355804863 3.130953333 0.501057644 -2.34182 0.0432761 
Id1 0.146931833 0.046371617 1.000955333 0.289310898 -6.81237 0.0434723 
Lrig3 0.0258732 0.007766843 0.074277133 0.014713731 -2.87082 0.0437101 
Arhgef16 0.132827167 0.044224052 0.336867333 0.054521309 -2.53613 0.043833 
Vps18 1.118062667 0.318328824 2.271316667 0.2378395 -2.03147 0.0440194 
Camkk1 0.536730333 0.090292375 2.115743333 0.537306663 -3.94191 0.0442009 
Zfp219 0.235465 0.061985251 0.476084 0.055243486 -2.02189 0.0442078 
Acbd4 0.571641333 0.111107103 1.441013333 0.278666451 -2.52084 0.0442098 
6720468P15Ri
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0.045236 0.019614105 0.136553067 0.024733836 -3.01868 0.0444376 
Nab2 0.346081 0.036210664 1.105848667 0.260281048 -3.19535 0.04451 
Emp2 0.075752267 0.021365758 0.157316667 0.018432033 -2.07673 0.0445379 
Npepl1 2.664 0.400419357 6.044606667 1.100934452 -2.269 0.0447548 
Slc7a8 3.37125 1.289559406 8.191066667 1.068823908 -2.42968 0.0451199 
Tbc1d16 0.530487667 0.066321796 1.062001333 0.172492556 -2.00193 0.0451904 
S1pr2 0.403628667 0.047086806 0.901655 0.166869446 -2.23388 0.0453609 
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Dcxr 1.477703 0.533433299 3.781873333 0.604437879 -2.55929 0.0460133 
Plcxd1 0.252671333 0.068421335 0.593477333 0.097673803 -2.34881 0.0460315 
Adamts10 2.189146667 0.398936574 4.395423333 0.66363638 -2.00783 0.0464269 
Pnldc1 0.034744033 0.007606913 0.239081 0.071346524 -6.88122 0.0464963 
Rhbdl3 0.020267333 0.00742295 0.076540467 0.018325571 -3.77654 0.046578 
Bmf 0.109213367 0.041596344 0.241063667 0.02045354 -2.20727 0.0466557 
Fosb 0.0901801 0.02023592 0.557517667 0.163134742 -6.18226 0.0467281 
Thop1 0.243245667 0.090000303 0.675569667 0.122788091 -2.77731 0.0468793 
Exoc3l 0.699345 0.173667013 1.566436667 0.251204059 -2.23986 0.0469006 
Pcsk9 0.020261933 0.010920858 0.073802167 0.015380832 -3.64241 0.0469495 
Crtc1 0.639868667 0.163663243 1.535896667 0.270200515 -2.40033 0.0470387 
Mir5121 0.127317333 0.127317333 0.636358667 0.126625167 -4.99821 0.0471125 
Acsf2 0.377635667 0.058366519 1.191637333 0.281304814 -3.15552 0.0471854 
Mesp2 0.0896901 0.053299256 0.272647333 0.036684767 -3.03988 0.0474601 
Dnmt3aos 0.027987567 0.007905636 0.080474567 0.016827384 -2.87536 0.047677 
Kcnd1 0.251367 0.089683167 0.578410333 0.073350868 -2.30106 0.0476942 
Majin 0.098611167 0.02599177 0.214736 0.031915442 -2.1776 0.0477665 
Tmem132a 0.037861267 0.016586677 0.101189933 0.015129659 -2.67265 0.0477886 
Klc4 1.223043333 0.143745627 2.531583333 0.441511425 -2.06991 0.0479167 
Tspan9 0.277069333 0.087714947 0.748571667 0.142673346 -2.70175 0.0480589 
Gpr162 0.120073867 0.049062241 0.268409667 0.019718883 -2.23537 0.0485478 
Gm5820 0.005728433 0.005728433 0.0486652 0.014219787 -8.49537 0.0487728 
Dhrs13 0.234833333 0.041384683 0.481983667 0.078163736 -2.05245 0.0490891 
Rgs14 0.991107667 0.069667347 2.312416667 0.468153648 -2.33317 0.0492288 
Polm 0.192991 0.030342036 0.613705333 0.147983046 -3.17997 0.0495621 
Irak4 4.985333333 0.401397089 12.31314333 2.600468399 -2.46987 0.0495692 
Fam220a 0.632410333 0.141130309 1.266347667 0.178805959 -2.00241 0.0496679 


















Table 2.3 Differentially Expressed Genes with Changes in TSS 
H3K27me3  
Gene Control Avg 
RPKM 








Nlrp1b 0.049862033 0.864582333 Increased Decreased 
Id1 0.146931833 1.000955333 Increased Decreased 
Dhx40 0.423009333 2.32885 Increased Decreased 
Rara 0.064549367 0.252864333 Increased Decreased 
Kdf1 0.040131233 0.1273811 Increased Decreased 
Dgkh 0.068762967 0.182805 Increased Decreased 
Arhgef16 0.132827167 0.336867333 Increased Decreased 
Fscn1 0.368342667 0.828328 Increased Decreased 
Wtip 0.076079967 0.166553 Increased Decreased 
Ear12 0.001324285 0.1078603 Increased Increased 
Slc7a3 0.0114649 0.105203367 Increased Increased 
Col4a6 0.002996367 0.026955533 Increased Increased 
Hopx 0.005080333 0.042597667 Increased Increased 
Rapgefl1 0.139962733 1.028098667 Increased Increased 
Chmp4c 0.0052634 0.036441533 Increased Increased 
Dmrtc1a 0.011771867 0.066270833 Increased Increased 
Slc1a4 0.042971733 0.172579333 Increased Increased 
Gpr173 0.0191817 0.071685033 Increased Increased 
Cxcr3 0.1639044 0.609519 Increased Increased 
Hist1h2bp 0.140177867 0.511851 Increased Increased 
Gpr165 0.031732167 0.115731667 Increased Increased 
Edn3 0.012419633 0.042557167 Increased Increased 
Tspan7 0.161131 0.461752 Increased Increased 
Ooep 0.063253567 0.177426667 Increased Increased 
Chchd2 15.03397 38.0728 Increased Increased 
Syt3 0.075596867 0.190738667 Increased Increased 
Acbd4 0.571641333 1.441013333 Increased Increased 
Boc 0.1087929 0.264007667 Increased Increased 
Ap5b1 0.173386333 0.411751333 Increased Increased 
Actn3 0.0728614 0.170465333 Increased Increased 
Plekhf1 0.477408 1.097690333 Increased Increased 
Pacrgl 1.155256 2.620743333 Increased Increased 
Guk1 6.10286 13.67083333 Increased Increased 
Nle1 3.55372 7.897536667 Increased Increased 
S1pr3 0.217457667 0.481747333 Increased Increased 
Magee1 0.347435 0.710094 Increased Increased 
P2ry10 0.562403333 1.139546667 Increased Increased 
Rarg 0.231730333 0.465601333 Increased Increased 
Tbc1d16 0.530487667 1.062001333 Increased Increased 
Gria3 2.244773333 1.075127333 Decreased Increased 
Nlrp1a 0.276917 0.047135067 Decreased Increased 
Nostrin 0.129872633 0.018865233 Decreased Increased 
Sbspon 0.068623033 0.009503133 Decreased Increased 





Table 2.4: Genotyping Primers 
 
Gene Primer Sequence 
Kdm6b WT/Fl Universal Forward GCGAGAGACCTGAGGCATGA 
Kdm6b WT Reverse CTCGCCTCCACCAGAGTCTT 
Kdm6b Fl/KO Reverse AGGGGGAAGAGCTTGCACAC 
GAPDH Forward (RT-PCR) AATTTGCCGTGAGTGGAGTC 
GAPDH Reverse (RT-PCR) TGGCAAAGTGGAGATTGTTG 
Vav-CRE Forward AGATGCCAGGACATCAGGAACCTG 
Vav-CRE Reverse ATCAGCCACACCAGACACAGAGATC 
Mx-1 CRE Forward CTGGGGATTGCTTATAACACCC 
Mx-1 CRE Reverse TCATCAGCTACACCAGAGACGG 
GAPDH Forward (Cre genotyping) GCAAGGTCATCCCAGAGC 
GAPDH Reverse (Cre genotyping) TGCAGCGAACTTTATTGATGGTATT 
Utx1  Forward GAGAAAGGAAATGTGAGAGC 





























Table 2.5: Flow Cytometry Panels  
 
Cell Type Tissue Immunophenotype 
Lineage - Myeloid Blood, WBM, 
Spleen 
CD45.2+, Mac-1+, Gr-1+ 
Lineage – B-cells Blood, WBM, 
Spleen 
CD45.2+, B220+ 
Lineage – T-cells Blood, WBM, 
Spleen 
CD45.2, CD3e+ 
Hematopoietic stem cells 
(HSC) 
(Naïve) 
WBM, Spleen Lineage- (Mac-1, Gr-1, B220, CD3e, Ter119), 
CD48-,  EPCR+, c-Kit+, Sca-1+, CD150+ 
Hematopoietic stem cells 
(HSC) 
(post-pIpC) 
WBM Lineage- (Mac-1, Gr-1, B220, CD3e, Ter119), 
CD48-,  EPCR+, c-Kit+, CD150+ 
Hematopoietic stem cells 
(HSC) 
(post-5-FU) 
WBM Lineage- (Gr-1, B220, CD3e, Ter119), CD48-,  
EPCR+, Sca-1+, CD150+ 
Multipotent Progenitors (MPP) WBM, Spleen Lineage- (Mac-1, Gr-1, B220, CD3e, Ter119), 
CD48-,  EPCR+, c-Kit+, Sca-1+, CD150- 
Restricted Progenitors (RP) WBM Lineage- (Mac-1, Gr-1, B220, CD3e, Ter119), 
CD48+,  EPCR+, c-Kit+, Sca-1+, CD150- 
Total Common Lymphoid 
Progenitors (CLP) 
WBM Lineage- (CD3e, B220, Mac-1, Gr-1, Ter119), 
c-Kit+, Sca-1low, Flk2+, IL7RA+ 
Common B-cell lymphoid 
progenitors (CLP-B) 
WBM Lineage- (CD3e, B220, Mac-1, Gr-1, Ter119), 
c-Kit+, Sca-1low, Flk2+, IL7r+, Ly6D+ 
Immature B-cells WBM B220+, IgM+ 
Pre-Pro-B-cells WBM B220+, IgM-, CD43+, CD19- 
Pro-B-cells WBM B220+, IgM-, CD43+, CD19+ 
Pre-B-cells WBM B220+, IgM-, CD43-, CD19+ 
Early thymic progenitor (ETP) Thymus CD4- CD8a- Lineage- (Mac-1, Gr-1, B220, 
NK1.1, CD11c, Ter119, CD3e), CD25- c-Kit+ 
Double negative 1 (DN1) Thymus CD4- CD8a- Lineage- (Mac-1, Gr-1, B220, 
NK1.1, CD11c, Ter119, CD3e), CD25- CD44+ 
Double negative 2 (DN2) Thymus CD4- CD8a- Lineage- (Mac-1, Gr-1, B220, 
NK1.1, CD11c, Ter119, CD3e), CD25+ c-Kit+ 
Double negative 3 (DN3) Thymus CD4- CD8a- Lineage- (Mac-1, Gr-1, B220, 
NK1.1, CD11c, Ter119, CD3e), CD25+ c-Kit- 
Proerythroblasts Spleen Lineage- (CD3e, B220, Gr-1, Mac-1), CD71+, 
Ter119low 
Maturing Erythroblasts Spleen Lineage- (CD3e, B220, Gr-1, Mac-1), CD71+, 
Ter119+ 








Table 2.6: Flow Antibodies 
 






CD45.1 FITC BioLegend A20 110706 1:100 
CD45.2 BV421 BioLegend 104 84208 1:100 
CD45.2 BV605 BioLegend 104 109841 1:100 
CD45.2 PE BioLegend 104 109808 1:100 
B220 PECy7 BioLegend RA3-6B2 103222 1:100 
B220 APC BioLegend RA3-6B2 103212 1:100 
B220 APCCy7 BioLegend RA3-6B2 103224 1:100 
Gr-1 PECy7 BioLegend RB6-8C5 108416 1:100 
Gr-1 APCCy7 BioLegend RB6-8C5 108424 1:100 
Mac-1 PECy7 BioLegend M1/70 101216 1:100 
Mac-1 APCCy7 BioLegend M1/70 101226 1:100 
CD3e APC BioLegend 145-2C11 100312 1:100 
CD3e APCCy7 BioLegend 145-2C11 100330 1:100 
Ter119 APCCy7 BioLegend TER-119 116223 1:100 
NK1.1 Biotin eBiosciences PK136 13-5941-
85 
1:100 
CD11c Biotin eBiosciences N418 13-0114-
82 
1:100 
Streptavidin APCCy7 BD 
Biosciences 
 554063 1:100 
CD48 PECy7 BioLegend HM48-1 103424 1:100 
CD150 PE BioLegend TC15-
12F12.2 
115904 1:100 
CD150 BV421 BioLegend TC15-
12F12.2 
115925 1:100 






c-Kit BV421 BioLegend 2B8 84158 1:100 
c-Kit APC BD 
Biosciences 
2B8 561074 1:100 
c-Kit FITC BD 
Biosciences 
2B8 561680 1:100 
Sca-1 FITC BD 
Biosciences 
E13-161.7 553335 1:100 
Sca-1 APC BioLegend E13-161.7 122512 1:100 
Flk2 PE BD 
Biosciences 
A2F10.1 553842 1:50 
IL7r APC BioLegend A7R34 135012 1:50 
Ly6D FITC BD 
Biosciences 
49-H4 561148 1:100 
CD16/32 PE eBiosciences 93 12-0161-
82 
1:50 
CD34  FITC BD 
Biosciences 
RAM34 560238 1:50 
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CD34  APC BioLegend MEC14.7 119310 1:50 
IgM PECy7 eBiosciences II/41 25-5790-
82 
1:100 
CD43 PE eBiosciences EBioR2/60 12-0431-
83 
1:100 
CD19 FITC eBiosciences eBio1D3 11-0193-
85 
1:100 
CD4 APC eBiosciences GK1.5 17-0041-
81 
1:100 
CD8a PECy7 BD 
Biosciences 
53-6.7 552877 1:100 
CD44 BV421 BioLegend IM7 103039 1:100 
CD25 PE eBiosciences PC61.5 12-0251-
83 
1:100 
CD71 APC eBiosciences R17217 17-0711-
82 
1:100 
H2AX Alexa Fluor 
647 





F21-852 552933 2:5 
Ki67 BV605 BioLegend 16A8 652413 1:10 
 
 
Table 2.7: TaqMan Gene Specific Probes for qRT-PCR 
 






















Chapter 3: Discussion 
3.1 Conclusions 
3.1.1 Introduction 
The balance between self-renewal and differentiation is critical for HSCs in normal 
hematopoiesis as well as HSCs undergoing proliferative, oncogenic, and inflammatory 
stress.  Epigenetic modifiers with varied functions have been identified as being frequently 
mutated in numerous different leukemias and blood disorders including enzymes involved 
in DNA methylation, DNMT3A and TET2, and enzymes involved in H3K27me3 
methylation, UTX, and EZH2115–117.  Research driven to elucidate the function of such 
genes have shown that in normal hematopoiesis aberrant expression can result in an 
imbalance of HSC fate decisions.  Loss of Dnmt3a results in an increase in self-renewal 
and diminishes differentiation157.  Competitive transplants of Tet2-KO HSCs from both 
adult WBM and fetal liver cells showed increased repopulating capacity, expansion of 
progenitors, and altered hematopoietic differentiation skewed toward myeloid lineages158–
160.  Conversely, loss of Ezh2, has been shown to alter fetal and adult hematopoiesis in 
different ways, with it being essential in embryonic hematopoiesis and redundant with 
Ezh1 in adult WBM124.   
In addition to being mutated, epigenetic modifiers have also been identified as 
being dysregulated including KDM2B, which is the H3K36me2 demethylase, and is 
upregulated in T-cell lymphomas and AML161.  Analysis of Kdm2b deficient mice indicate 
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that not only is Kdm2b necessary for leukemia initiation and maintenance of disease161, 
but that loss of Kdm2b leads to a loss in HSCs and progenitors and skews differentiation 
to myeloid bias162.  Given that KDM6B is also seen to be overexpressed in blood cancers 
but rarely mutated92,120–122, we aimed to elucidate the role that KDM6B plays in normal 
and malignant hematopoiesis.   
3.1.2 Kdm6b in Stem Cell Fate Decisions 
 Similar to what has been seen in other mouse models, the loss of Kdm6b 
drastically influences that stem cell fate decisions between self-renewal and 
differentiation.  Here we show that loss of Kdm6b leads to a reduction in phenotypic and 
functional HSCs and MPPs.  Additionally, we showed that while complete ablation of 
Kdm6b leads to this phenotype quickly, it acts in a dose dependent manner, with Kdm6b-
HetVAV eventually losing phenotypic HSCs and MPPs with age, or with serial transplants.  
Transplantation of HSCs with reduced expression of Kdm6b showed that they are 
capable of making all three lineages, but not to sustain the progenitor compartment.   
Taken together, our data suggests that Kdm6b is necessary for the self-renewal of HSCs, 
and one of the reasons that deletions may not be seen in leukemia is due to the fact that 
HSCs with mutated KDM6B are rapidly outcompeted and lost in the HSC pool.   
 We also observed that loss of Kdm6b leads to a phenotype that is very similar to 
that of aged HSCs.  This may suggest that as people age, KDM6B is not capable of 
responding to environmental queues either inflammatory or proliferative, or that it has 
decreased expression in HSCs.  Interestingly, Kristina Kirschner et al recently studied 
aging HSCs to identify a molecular signature that characterizes the population and many 
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of the genes they identified are significantly upregulated in Kdm6b-KOVAV HSCs163 
(p=3.8655x10-8) (Figure 3.1, Table 3.1) and are related to stress response. 
3.1.3 Regulation of Stress Response in Hematopoiesis Requires 
Kdm6b 
 While we did see a significant reduction HSCs and MPPs in non-manipulated mice, 
aging mice did not lead to overt hematopoietic disease.  Rather, the transplantation of 
WBM and HSCs led to a more overt self-renewal phenotype indicating that the 
proliferative stress of inflammatory environment may contribute to the phenotype of 
Kdm6b-KOVAV HSCs.  One of the roles KDM6B plays in cells that has been widely studied 
is its role in inflammatory and environmental stresses59,72,84.  Hematopoetic stem and 
progenitor cells were discovered to have toll-like receptors on their surface making them 
immunogenic123.  This indicates that Kdm6b may be playing an important role in stress 
response in HSCs.  Our RNA-SEQ indicated that loss of Kdm6b in HSCs leads to an 
increase in inflammatory signaling pathways including, NF-κB and IFNγ.  Interestingly, 
numerous genes implicated in these pathways are overlapping and have been identified 
as driving HSC quiescence139, as being immediate early response genes (IERs)164, and 
as being top genetic markers defining aged HSCs163 (Table 3.1).  These overlapping 
genes include but are not limited to: Fos, Fosb, Jun, Dusp1, Egr1, Ier3, and Zfp36.  
 Macrophage response to LPS stimulation indicated that, with the exception of 
Bmp-227, gene expression changes in the absence of Kdm6b is demethylase-
independent72.  Our ChIPmentation data for H3K27me3 indicates that the changes in 
gene expression driven by the loss of Kdm6b is also demethylase-independent.  While 
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there were differences in peaks between control and Kdm6b-KO HSCs, they did not 
correlate with changes in gene expression.  Previous experiments suggest that KDM6B 
may play a role in H3K4me3 in stress response in MDS122, however, ChIPmentation for 
H3K4me3 showed no differences with 99.9% of the peaks overlapping.  Taken together 
this suggests that loss of Kdm6b in HSCs leads to a proinflammatory state that is not 
dependent upon the previously identified chromatin modifications with which Kdm6b 
identifies. 
 The dysregulation in inflammatory signaling led us to explore the effect that varying 
stress agents would have on Kdm6b-KOVAV HSCs.  We saw that upon pIpC treatment, 
which mimics a viral infection and INFα response136, HSCs lacking Kdm6b were no longer 
able to compete short-term in transplantation.  In non-manipulated primary mice, two 
short pIpC treatments indicated that upon inflammatory stress, while controlVAV HSCs are 
capable of expanding the HSC population as well as the progenitor pool, Kdm6b-KOVAV 
HSCs did not show an increase, but their progenitor population did.  This suggests that 
Kdm6b is required for self-renewal of HSCs exposed to inflammatory stress.  To 
compliment this, we saw that while Kdm6b-KOVAV mice were able to regenerate the 
hematopoietic compartment after 5-FU, upon serial exposure they had a significant 
decrease in survival.  Additionally, both 5-FU and pIpC treatment caused the inflammatory 
genes already upregulated in Kdm6b-KOVAV HSCs to become even more so.  Altogether, 
our experimental data suggests that Kdm6b plays an integral role in stress response and 




3.1.4 Kdm6b as a Therapeutic Target for AML 
 When we explored the role of Kdm6b in leukemic stem cells under oncogenic 
stress using the MLL-AF9 model, we saw that loss of a single allele or both alleles of 
Kdm6b leads to significant increases in survival and a reduction in leukemic stem cells.  
This suggests that KDM6B could be a potential therapeutic target of AML as well as the 
previously identified MDS, multiple myeloma and T-ALL120–122.  
A small chemical inhibitor, GSK-J4, was identified in 2012 as a H3K27me3 
demethylase inhibitor that shows specificity to KDM6B and UTX28.  This small molecule 
inhibitor works by mimicking α-ketoglutarate and preventing the binding of that necessary 
cofactor28.  Since then many studies have looked at the power of inhibiting KDM6B in 
vitro, however, given that the inhibitor works on both demethylases  it may have 
unintended consequences. In NICD driven T-ALL, UTX had been shown to play a tumor 
suppressor role while KDM6B acts as an oncogene120.  One could argue that inhibiting 
KDM6B may be therapeutic, but concurrent inhibition of UTX may lead to a more 
aggressive disease.  In example, while the previous paper by Ntzizchristos et al  
suggested that GSK-J4 is acting by inhibiting KDM6B in NICD driven T-ALL,  Benyoucef 
et al showed that in TAL1 driven T-ALL GSK-J4 is acting by inhibiting UTX, which is an 
activator of TAL1165.  This ambiguity of the mechanism of action of GSK-J4 is an example 
of why more specific inhibitors are needed.  It was shown that altering the structural 
design of GSK-J4 with different chelating groups to disrupt Fe(II) interactions may create 




3.2 Future Directions 
3.2.1 Combinatorial Treatment of IFN and KDM6B inhibition 
 We have shown that Kdm6b is required for normal and leukemic stem cell self-
renewal, and that loss of Kdm6b leads to increased survival in MLL-AF9 driven leukemia.  
Further loss of Kdm6b leads to the inability for progenitor cells to respond correctly to 
inflammatory and stress signals, and stimulating Kdm6b-KOVAV HSCs to proliferate under 
stress leads to a differentiation cascade and eventual loss of the HSC compartment.  
Currently, we still need to investigate if pharmacological inhibition of Kdm6b using GSK-
J4 also increases the survival of controls. Further, treating Kdm6b-KOVAV mice 
transplanted with MLL-AF9+ transduced WBM with INFγ or pIpC may create a 
combinatorial effect and a more efficacious therapy.   
3.2.2 Fos/Jun AP-1 Transcription Factor as a Possible Regulator of 
Kdm6b Demethylase-Independent Gene Expression  
 Despite the overall amount of work that has already gone into this project, the one 
piece of evidence we are missing is the exact mechanism by which Kdm6b is acting in 
HSCs.  While we have shown that loss of Kdm6b in HSCs leads to demethylase-
independent changes in gene expression with the majority of genes increasing in 
expression, we have not elucidated what is causing these gene expression changes.  Of 
the genes that consistently show up as being involved in dysregulated pathways, two may 
hold the key: Jun and Fos.  These two genes form the AP-1 transcription factor that like 
KDM6B has been shown to be necessary for neuronal development and repair167,168, 
epidermal differentiation169–172, stress-response173–176, and TPA-induced HL-60 
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differentiation177,178.  As IER genes they are immediately increased in expression upon 
stress stimulus and bind to the TPA-inducible enhancers (TRE) with the consensus 
binding site TGA(C/G)TCA179.  Importantly, it has also been shown that AP-1 acts in a 
positive autoregulatory loop, where TPA causes AP-1 to bind to the Jun promoter and 
increase its own expression180.  It has also been shown that AP-1 can increase 
glucocorticoids which in turn downregulate AP-1 activity181, indicating that AP-1 target 
genes can serve as negative feedback loops for the transcription factor. 
The macrophage stress-response promoter found in the first intron of Kdm6b 
contains two AP-1 TRE consensus sites, in addition to two NF-κB binding sites27,104.  After 
LPS treatment in macrophages it was shown that NF-κB binds to this promoter resulting 
in increased Kdm6b expression27.  KDM6B was shown to be necessary for TPA-induced 
HL-60 differentiation, and it has been identified as a TPA response gene70 in addition to 
the IER genes FOS and JUN177,178.  We hypothesize that in HSCs Kdm6b is a direct target 
of the AP-1 transcription factor containing Jun and Fos and that Kdm6b loss leads to the 
inability to regulate the feedback loop necessary to silence the AP-1 pathway in HSCs.  
In support of this, of the 49 previously identified IER genes, there is significant overlap, 
with 12 being overexpressed greater than 2-fold in Kdm6b-KOVAV HSCs (p=1.6485x10-9) 
(Table 3.1).  Additionally, Erg1, another highly dysregulated inflammatory gene, has been 
shown to interact with AP-1 at its consensus binding sites182.  To test this, we will perform 
chromatin immunoprecipitation for FOS and JUN in HL-60 cells that are treated with PBS 
or stimulated to differentiation with TPA.  Following this we will perform qPCR for the 
KDM6B promoter regions that contain the AP-1 binding motif.  This will allow us to show 
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the direct interaction between the AP-1 transcription factor and KDM6B in response to 
stress and differentiation. 
3.2.3 Does Genetic Inhibition of AP-1 Transcription Factor Genes 
Rescue Kdm6b Phenotype? 
 Because the AP-1 transcription factor was one of the first discovered, it has been 
widely studied in a variety of systems.  The expression patterns of FOS and JUN  been 
seen to be highly specific in human keratinocytes170 and suppression of the AP-1 
transcription factor in this system prevents differentiation142.  The differential expression 
pattern of FOS showed that expression of the gene is not high in hematopoietic tissue 
unless it is undergoing differentiation, and it exhibits similar patterns in differentiating fetal 
membranes183.  Induced prolonged expression of Fos in transgenic mouse HSCs caused 
decreased colony forming potential and forced the HSCs into G0/G1, but Fos-KO HSCs 
had no deficiencies143.  Taken together, this indicates that the expression of Fos is highly 
regulated within the hematopoietic system, and aberrant expression can effect both HSC 
and differentiation.  We hypothesize that the increased expression of Fos and Jun in 
Kdm6b-KOVAV HSCs contributes to phenotype we observed and that reduction of their 
expression will lead to increased engraftment and restored inflammatory stress response.   
 We have generated shRNAs targeting Fos and Jun in GFP+ and mCherry+ 
constructs, respectively, as well as shLacZ controls.  We will perform double transduction 
on c-Kit+ enriched WBM from controlVAV or Kdm6b-KOVAV mice.  These cells will be 
competitively transplanted and allowed to engraft.  At four weeks post-transplant, we will 
treat the recipient micce with six-doses of pIpC for 12-days, and two-weeks post-
treatment analyze HSCs.  This system will allow us to see if reduction of Fos, Jun, or both 
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Fos and Jun concurrently are contributing to the phenotype.  We will perform a similar 
experiment overexpressing Fos and Jun in controlVAV HSCs to determine if 
overexpression phenocopies loss of Kdm6b.  
 Taken together, these experiments should contribute to identifying the mechanism 
behind the phenotype we observed and should add significantly to the scientific 
























Figure 3.1 Aged HSC Gene Expression Signature 
 
 
RPKM values from RNA-SEQ of the top 20 genes driving the aged HSC gene 
expression signature as identified by Kristina Kirschner et al163 with significantly 











Table 3.1: Overlapping Gene Signatures in Kdm6b-KOVAV HSCs 
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